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Zusammenfassung  
 
Endostatin und Restin sind proteolytische Spatprodukte von Kollagen XVIII bzw. XV. Sie 
sind in der Literatur als anti-angiogenetische und aufgrund dessen tumor-inhibierende 
Proteine beschrieben. Die Verteilung von Endostatin und Restin sowie die Verteilung ihrer 
Bindungsstellen im Embryoid Body (EB), im Embryo und bei der Wundheilung deutet darauf 
hin, dass sie eine wichtige Rolle bei der Gefäßentwicklung spielen. Bezogen auf die 
Gefäßentwicklung differenzierter embryonaler Stammzellen zeigten diese beiden Faktoren 
sowohl eine angiogenetische als auch eine anti-angiogentische Wirkung, da sie auf für die 
Gefäßentwicklung und Gefäßneubildung entscheidende Prozesse, wie Proliferation, Migration 
der Endothelzellen einen steigernden Einfluss nehmen. Andererseits jedoch induzieren sie 
Apoptose in Endothelzellen. Die Wirkung von Endostatin und Restin auf die 
Gefäßneubildung kann somit als angio-modulatorisch bezeichnet werden. Endostatin und 
Restin nehmen jedoch nicht nur Einfluss auf die endotheliale Proliferation, Migration und 
Apoptose, sondern beeinflussen auch die Morphogenese der Gefäßanlagen in Form einer 
Kontraktion oder Retraktion, was sowohl mittels vitalmikroskopischer Beobachtung und 
Dekonvolutionsmikroskopie von embryonalen Gefäßen deutlich wird, als auch bei der 
elektronenmikroskopischen Betrachtung neugebildeter Gefäße während der Wundheilung 
ersichtlich ist. Die Beeinflussung der Morphogenese führt zur Frage, welche 
Signaltransduktionswege einbezogen sind. Insbesondere für die Morphogenese legen 
Vorbefunde nahe, dass eine die Regulation über den VEGF-Signalwegs oder von Molekülen 
des VEGF-Signalwegs geschieht. Eine Betrachtung der Endostatin- und Restin-Wirkung auf 
zellulärer Ebene brachte zum Vorschein, dass diese Faktoren tatsächlich Einfluss auf 
Signalmoleküle in Endothelzellen nehmen. Und zwar kommt es unter Einfluss von Endostatin 
und Restin zu einer Dephosphorylierung der aktivierten ERK1/2-Kinase sowie zu einer 
Runterregulation der löslichen Guanylat Cyclase (sGC) innerhalb eines Zeitraums von 6 
Stunden. Diese endostatin-vermittelte Beeinflussung der Signaltransduktion ist über die 
Protein-Phosphatase 2A (PP2A) induziert, da eine Hemmung der PP2A sowohl eine 
Dephosphorylierung der aktivierten ERK1/2-Kinase als auch die Runterregulation der 
löslichen Guanylat Cyclase verhindert. Die Dephosphorylierung der aktivierten ERK1/2-
Kinase ist mit Hilfe von zusätzlichem cGMP aufhebbar. Modulatorische Versuche unter 
Verwendung von cGMP und ODQ legen nahe, dass cGMP unter definierten Bedingungen 
diese Dephosphorylierung der aktivierten ERK1/2-Kinase stabilisieren kann. 
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Summary  
 
Endostatin and restin are proteolytic fragments of collagen XVIII and XV. They are described 
in literature as anti-angiogenic and consequently tumour-inhibitory proteins. The observation 
of endostatin and restin distribution as well as the distribution of their binding sites in the 
Embryoid Body (EB), in the embryo and during wound healing, suggests that they have an 
important role during vessel development. During vessel development of differentiated 
embryonic stem cells this two factors show both, an angiogenic and an anti-angiogenic effect 
by increasing endothelial proliferation and migration, processes which play an important role 
for vessel development and neovascularisation. On the other hand they induce endothelial 
apoptosis. The effect if endostatin and restin on neovascularisation and vessel development 
can therefore be described as an angio-modulatory. But endostatin and restin do not only 
influence endothelial proliferation, migration and apoptosis, they also influence endothelial 
morphogenesis by inducing a contraction or retraction of vessels. This phenomena was 
observed by vital-microscopy and deconvolution microscopy of embryonic vessels as well as 
during wound healing. The influence on morphogenesis leads to the question to which 
signaling pathways are involved. Especially for the morphogenesis our results imply that 
these processes are regulated by the VEGF signaling pathway or by molecules of the VEGF-
signaling pathway. On cellulary level endostatin and restin show an influence of signaling 
molecules in endothelial cells. They lead to a dephosphorylation of the activated ERK1/2-
kinase as well as to a down-regulation of the solouble Guanylate Cyclase (sGC) in a time 
course of 6 hours. The modulation of signaltransduction is induced by the protein phosphatase 
2A (PP2A) because of the fact that inhibition of PP2A prevents dephosphorylation of 
activated ERK1/2-kinase and down-regulation of the sGC. The dephosphorylation of the 
activated ERK1/2-kinase is preventable by additional cGMP. Modulatory experiments by 
using cGMP and ODQ suggest that cGMP, under definitive conditions is able to stabilise the 
phosphorylation of the activated ERK1/2-kinase. 
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1. Introduction  
 
1.1 Vessel Development 
 
1.1.1 Angiogenesis and vasculogenesis 
Already in 1508 Leonardo da Vinci speculated that human circulation and vessel system 
develop in analogy to the botanical example: the tree, the heart with sprouting roots, the liver 
capillary network, and a trunk with major branches, the aorta and arteries. Later it emerged 
that the vascular system is determined before the heart starts beating (Risau 1997). Today it is 
known that the early vascular network is formed from mesoderm by differentiation of 
angioblasts. Angioblasts form primitive blood vessels. The cell biological mechanism which 
is responsible for this process is called vasculogenesis. The differentiation of angioblasts from 
mesoderm and formation of primitive blood vessels by angioblasts are two different steps 
during early embryonic vasculogenesis (Risau and Flamme 1995). However angioblasts do 
not only form blood vessels at places of genesis, rather they migrate over long distances, 
forming a vascular plexus at a distant site (Noden 1991). After a primary vascular network is 
formed, more endothelial cells are generated, which can form new capillaries by sprouting or 
by splitting from their vessels of origin in a process termed angiogenesis (Risau 1997). The 
sprouting angiogenesis occurs mainly in the yolk sac and in the embryo and includes the 
proteolytic degradation of extra cellular matrix. Afterwards a chemotactic migration and 
proliferation of endothelial cells, with lumen formation and functional maturation of the 
endothelium follow (Risau 1997). During non-sprouting angiogenesis vessels arise by 
splitting pre-existing vessels from transcapillary pillars or posts of extra cellular matrix (Short 
1950). In vivo non-sprouting angiogenesis can occur by proliferation of endothelial cells 
inside a vessel, producing a wide lumen that can be split by transcapillary pillars, or fusion 
and splitting of capillaries (Pardanaud et al. 1989). The emerging vascular plexus is rapidly 
remodelled to resemble a mature system with larger and smaller vessels. The responsible 
process is termed pruning (Risau 1997). The maturation of big vessels includes the 
differentiation of smooth muscle cells and the formation of the lamina elastica interna. 
Formation of a luminal tubus is the key event during endothelial cell maturation and includes 
differentiation of polarised and functional different cell surfaces (Risau 1995).  
The vascular development is modulated by endostatin and restin                                                               page 2 
1.1.2 Stimulators of angiogenesis 
Processes like angiogenesis and vascular remodelling involve endothelial proliferation as well 
as regression of endothelial cells and they are thereby determined by different growth factors. 
For example bFGF (basic fibroblast growth factor) and VEGF (vascular endothelial growth 
factor) contribute synergistically to the regulation of blood vessel formation (Pepper et al. 
1992) and are very important factors regarding neovascularisation and vessel development as 
well as for endothelial morphogenesis. They are suggested to induce proliferation, migration 
and differentiation of angioblasts in vitro. BFGF seems to play a major role in the induction of 
angioblasts whereas VEGF appears to determine the initiation of morphogenesis leading to 
the initial vascular pattern. Moreover, VEGF has been reported to augment the population of 
endothelial precursor cells (EPCs) in vivo (Kalka et al. 2000). Kazemi et al. could show that 
bFGF and VEGF influence survival of angioblasts and that VEGF cause differentiation of 
angioblasts whereas bFGF does not suggesting a differential role of these factors for 
vasculogenesis (Kazemi et al. 2002). Capillary endothelial cells of embryonic tissue and 
organs do not express perceptible amounts of FGF-receptor coding mRNA (Heuer et al. 1990, 
Wanaka et al. 1991, Peters et al. 1992). Endothelial cells of bigger vessels however express 
FGF-receptor and react on FGF treatment in vivo (Peters et al. 1992, Lindner et al. 1990, Liaw 
and Schwartz 1993). Flk-1 (VEGFR-2) is the first endothelial receptor to be expressed in 
angioblast precursors in the primitive mesoderm of the mouse and is required for angioblast 
differentiation, followed shortly later by Flt-1 (VEGFR-1), which is required for assembly of 
blood vessels (Breier et al. 1997).  
 
1.1.3 Inhibitors of angiogenesis  
Vasculogenesis and angiogenesis underlay a stringent control of stimulatory and inhibitory 
factors (Hanahan and Folkman 1996). Many tumours are able to produce angiogenic and anti-
angiogenic factors (Folkman 1990, Chen et al. 1995, Gately et al. 1996). In the past numerous 
angiogenesis inhibitors were identified and characterised. Among them the most important: 
Thrombospondin-1 is an adhesive glycoprotein with a size of 160 kDa and was found in the α
–granula of thrombocytes. Presumably it is involved in the stabilisation of thrombocyte 
aggregates (Phillips et al. 1980). In a series of studies it has been shown that thrombospondin-
1 suppress neovascularisation (Good et al. 1990). Also it inhibits angiogenesis and migration 
of endothelial cells whereas an inhibition of endothelial proliferation could not be shown 
(Klagsbrun and D’Amore 1991). Thrombospondin-1 is regulated by the tumour suppressor 
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protein p53 (Good et al. 1990). The complete thrombospondin-1 as well as its specific 
fragments are able to suppress angiogenesis (Good et al. 1990, Tolsma et al. 1993). On the 
contrary the potent angiogenesis inhibitors like endostatin and angiostatin are fragments of 
common extra cellular proteins, which by themselves do not participate in regulation of 
angiogenesis (Hohenester et al. 1998). Also the angiogenesis inhibitor platelet factor IV was 
found in the α–granula of thrombocytes and it is released during thrombocytes aggregation. It 
is a big tetrameric protein with a size of 28 kDa and was initially characterised by its high 
affinity to heparin (Walz and Hung 1985). Platelet factor IV was characterised as a potent 
anti-angiogenic factor (Taylor and Folkman 1982). It prevents angiogenesis and endothelial 
cell proliferation, whereas an inhibition of endothelial migration was not observed (Klagsbrun 
and D’Amore 1991). Therefore this inhibitor shows a comparable biological action to 
endostatin. Interferon-γ, a 50 kDa big protein inhibits like endostatin angiogenesis, endothelial 
migration and proliferation (Klagsbrun and D’Amore 1991). The angiogenesis inhibitor 
angiostatin is a fragment of plasminogen and has a size of 38 kDa. It suppresses angiogenesis 
and formation of metastasis (O’Reilly et al. 1994).  
 
1.1.4 Tumour vascularisation  
The proliferation of blood vessels is a necessary process for normal tissue growth (Folkman 
1971). Vasculogenesis and angiogenesis are subject to a stringent control of stimulatory and 
inhibitory factors (Hanahan and Folkman 1996). When in normal adult tissue vasculogenesis 
rests, the balance is lying presumably on the side of inhibitors, however during tumour 
expansion the balance is disturbed (Chang et al. 1999). In adult organisms angiogenesis 
appears rarely and it is part of a body internal reparation/regeneration system during healing of 
wounds or part of the female reproduction cycles (Klagsbrun and D’Amore 1991). Opposite to 
that an angiogenesis out of balance is often part of a pathological event, like during 
angiogenesis induced tumour growth (Folkman 1972). Tumour growth is angiogenesis 
dependent (Folkman 1971). An insufficient tumour vascularisation has the consequence that 
tumour cells become necrotic and/or apoptotic (Holmgren et al. 1995, Parangi et al. 1996). 
Following to a tumour genesis every increase in tumour cell population precedes an increase 
of vessel growth (Folkman 1990). Experiments regarding tumour growth and angiogenesis 
show that the growth rate of an implanted, subcutan tumour is low before vascularisation, 
however high and nearly exponential after vascularisation (Algire 1945). In correlation with 
an increased angiogenesis in tumours it was observed that many tumours are able to produce 
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angiogenic factors, which leads to an increased tumour expansion (Relf et al. 1997). Some 
malign tumours also produce angiogenic inhibitors (Chen et al. 1995, Gately et al. 1996). The 
increased angiogenesis during tumour growth could lead to an increase of metastases because 
neovascularisation could permit and support spreading of cells of the primary tumour (Liotta 
et al. 1974). On the other side a decrease of angiogenesis is associated with decreased 
metastasis (Starkey et al. 1988). The vascularisation of a tumour and the resulting metastasis 
are demonstrated in the following:  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.1: Vascular components of tumour metastasis (Zetter 1998). The steps of metastasis pathway that involve 
interactions with blood vessels: (a) small primary tumours (<2 mm) remain avascular until they (b) invade the 
local epithelia basement membrane. If the tumour cells produce angiogenic factors (c) angiogenesis will occur, 
allowing expansion of the primary tumour. (d) The new blood vessel provides a route of entry into the 
bloodstream and the tumour cells circulate until they die or (e) attach specifically to endothelial cells in the 
vessels (usually venules) of downstream organs. (f) The tumour cells extravasate through the vessel wall and the 
(g) migrate to sites proximal to arterioles where their growth is enhanced. (h) Micrometastases can remain 
dormant for extended time periods during which angiogenesis is suppressed. (i) Initiation of angiogenesis at the 
secondary site releases the metastatic colonies from dormancy and allows rapid growth. 
 
g  Migration 
i  Metastasation 
f  Extravasation 
e  Adhesion to the 
vessel 
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Primary 
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1.1.5 Wound Healing 
Wound healing is traditional divided into three phases-the inflammatory phase, the 
proliferation phase, and the remodelling phase. Injury to adult tissues initiates a series of 
events including inflammation, new tissue formation, and tissue remodelling (Clark 1996, 
Martin 1997). The formation of new tissue is initiated by migration and proliferation of 
keratinocytes at the wound edge within 1 day after injury. New stroma, often called 
granulation tissue, begins to form after a delay of 2 or 3 days. This tissue consists of 
inflammatory cells, fibroblasts. Loose connective tissue, and numerous capillaries that endow 
the neostroma with its granular appearance. The new capillaries are generated by sprouting 
from pre-existing vessels, in a process called angiogenesis. The later involves migration and 
proliferation of endothelial cells, lumen formation, and stabilisation of the new vessel by 
recruitment of associated supporting cells (Risau 1997, Augustin 1998). Wound angiogenesis 
is essential to support the regenerating tissue with oxygen and nutrition (Clark 1996). 
 
1.2 Signaltransduction  
 
Changes of the vascular system induced by growth factors, are mostly linked to receptor-
mediated signalling pathways. An exemplary pathway for such processes, but very important 
for this work is the VEGF/Flk-1/eNOS/NO/sGC/cGMP/ERK1/2 pathway. Vascular 
endothelial growth factor (VEGF) is a secreted protein that is a specific growth factor for 
endothelial cells (Ferrara and Henzel 1989, Keck et al. 1989). It is angiogenic in vivo and in 
vitro assays (Breier et al. 1992, Goto et al. 1993) and its physiological importance in 
vasculogenesis is well documented (Fong et al. 1995, Shalaby et al. 1995). The action of 
VEGF is regulated by two receptor belonging to the tyrosine kinase family Flt-1 and Flk-1 (De 
Vries et al. 1992, Terman et al. 1992). Flt-1, which has higher affinity for VEGF than Flk-1, is 
required for endothelial cell morphogenesis, whereas Flk-1 is involved in primarily 
mitogenesis (Fong et al. 1995, Shalaby et al. 1995, Waltenberger et al. 1994, Keyt et al. 1996). 
VEGF effects on permeability (Wu et al. 1996) and vascular tone (Ku et al. 1993) are coupled 
to nitric oxide (NO) production. Consistent with these findings, in the past it was 
demonstrated that NO production and cGMP elevation contribute to the angiogenic effect of 
VEGF (Morbidelli et al. 1996, Ziche et al. 1997). The activation of mitogen-activated protein 
kinase (MAPK) cascade by VEGF has been recently demonstrated (D’Angelo et al. 1995). 
MAPKs are important intermediates in signal transduction pathways and they are stimulated 
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by a variety of agents (Seger and Krebs 1995). The 44- and 42-kDa MAPK (ERK1/2) 
isoforms are ubiquitously expressed (Blenis 1993, Davis 1993). Finally, Parenti et al. were 
able to describe the postreceptor signalling pathway underlying VEGF actions on endothelial 
cells as Flk-1/eNOS/NO/sGC/cGMP/ERK1/2 cascade activated by VEGF (Parenti et al. 
1998). An example for the regulation of eNOS and consequently for the regulation of this 
pathway is the activation of eNOS by phosphorylation of eNOS at Ser1177. This activation 
leads to an increased NO-production, whereas the phosphorylation of the eNOS at Ser495 
decreases the NO-production (Dimmeler et al. 1999).  
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1.3 Endostatin 
 
In the year 1997 endostatin was identified first by a Harvard group and was described as an 
endogen inhibitor of angiogenesis and tumour growth (O’Reilly et al. 1997). It is a proteolytic 
fragment of the C-terminal end of collagen XVIII (α1(XVIII) collagen) with a size of 20-22 
kDa (O’Reilly et al. 1997). The α1(XVIII) collagen is a usual collagen, characterised by 10 
domains of tripelhelical repetitions which are separated by non-tripelhelical repetitions (Oh et 
al. 1994A and B, Rhen and Pihlajaniemi 1994). α1(XVIII) collagen contains a non-
collagenous domain (NC-1) which consists of 300 amino acids. The angiogenesis inhibitor 
endostatin is a component of this NC-1 domain and consists of 184 amino acids (Hohenester 
et al. 1998). By analysing the crystal structure of the proteolytic fragment of the NC1-domain 
of collagen XVIII, (Hohenester et al. 1998) a heparin-binding site was detected with the 
presence of an extensive basic patch formed by 11 arginine residues. Therefore Hohenester et 
al. suspected that endostatin inhibits angiogenesis by a competitive binding to heparan 
sulphate proteoglycans (HSPGs) to which normally angiogenesis stimulating factors bind. 
Also the heparin binding capability of endostatin was already used for its isolation from 
hemangioendothelioma-conditioned medium (O’Reilly et al. 1997). However Chang et al. 
could show, that binding of endostatin to components of the extracellular matrix, contrary to 
that of pro-angiogenic factors, is resistant to a treatment with heparinase. Further it has been 
shown that there is no competition between endostatin and pro-angiogenic factors for binding 
sites of the extra cellular matrix (Chang et al. 1999). Therefore the anti-angiogenic effect of 
endostatin could not be a consequence of displacement of pro-angiogenic factors (Chang et al. 
1999). The findings regarding heparin-binding capacity of endostatin and heparin necessity 
were mainly analysed biochemically by solid phase binding (Sasaki et al. 1998/99). This 
analysis led to the conclusion that the heparin-binding site of endostatin is necessary for its 
anti-angiogenic activity. On contrary Yamaguchi et al., analysing endothelial migration 
showed, that heparin binding is not necessary for endostatin’s anti-angiogenic effect. It is still 
unclear, though, whether the heparin binding site is necessary for the anti-angiogenic activity 
of endostatin (Sasaki et al. 1998, Sasaki et al. 1999, Karumanchi et al. 2001) or not (Chang et 
al. 1999, Yamaguchi et al. 1999). Further discussed binding sites for endostatin are glypican 
and tropomyosin, binding sites with a varying affinity (Karumanchi et al. 2001, MacDonalds 
et al. 2001). 
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Recombinant endostatin emerged as a specific inhibitor of endothelial cell proliferation in 
doses dependent manner. O’Reilly et al. could show that a systemic treatment of mice with 
0.3mg/kg/day endostatin leads to a prevention of metastasis and simultaneously to an 
inhibition of lewis-lung-carcinoma growth (O’Reilly et al. 1997), on the contrary endostatin 
treatment did not influence resting endothelial cells and did not induce drug resistance 
(Boehm et al. 1997). On the other hand mice deficient in the endostatin precursor collagen 
XVIII develop normally with limited evidence of disturbed vascular morphogenesis (O’Reilly 
et al. 1997, Fukai et al. 2002). Thus, collagen XVIII itself does not appear a relevant regulator 
of vascular development but releases its activity after proteolytic cleavage. Another effect of 
endostatin is the induction of apoptosis in endothelial cells (Dhanabal et al. 1999A, Dixelius 
et al. 2000). In endothelial cells a reduction of the anti-apoptotic protein Bcl-2 and Bcl-xL 
could be observed while the pro-apoptotic protein Bax remained unchanged (Dhanabal et al. 
1999A). Proliferation (Dhanabal et al. 1999B, Yamaguchi et al. 1999) and migration 
(Dhanabal et al. 1999B and C, Shichiri and Hirata 2001) of growth factor stimulated human 
umbilical vein endothelial cells (HUVEC), porcine pulmonary artery endothelial cells 
(PAEC), bovine aortic endothelial cells (BAEC) was also inhibited under influence of 
endostatin. For endostatin two different binding sites with varying affinity have been 
described. These binding sites are glypican and tropomyosin (Karumanchi et al. 2001, 
MacDonalds et al. 2001). 
 
Endostatin influences morphology of endothelial cells and vessels (Dixelius et al. 2000), 
wound healing (Bloch et al. 2000, Mundhenke et al. 2001), of tumour vessels (Mundhenke et 
al. 2001, Read et al. 2001) as well as of embryonic stem cell derived endothelial cells and 
tubes.  
 
Endostatin, which influences signalling molecules in endothelial cells, leads to a down-
regulation of MAP-kinase (ERK-1/2) (Knebelmann et al. 1999), influences signalling 
molecules c-myc and c-fos (Shichiri and Hirata 2001), activates PKA and increases 
intracellular cAMP (Shichiri and Hirata 2001), induces Shb tyrosine phosphorylation 
(Dixelius et al. 2000). It increases Ca2+-influx (Jiang et al. 2001) and influences VEGF-
receptors as well as phosphorylation of 38 MAKP and 125FAK (Kim et al. 2002). Endostatin 
has also an effect on the activity of endothelial NO-synthase (eNOS) by influence the 
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phosphorylation of Ser1177 (Urbich et al. 2002), which probably leads to a reduction of 
cGMP (Verma et al. 2002). Recently it has been shown that endostatin down-regulated the 
VEGF-expression in tumour cells (Hajitou et al. 2002). 
 
1.4 Restin 
 
Restin, a proteolytic fragment of collagen XV is described as an anti-angiogenic protein that 
inhibits tumour growth and endothelial migration (Ramchandran et al. 1999). Ramchendran et 
al. have shown that restin has 60% homology to endostatin. It decreases tumour volume by 
30% and did not bind to heparin. Collagen XV is like collagen XVIII a basement membrane 
collagen (Sasaki et al. 2002). Both are members of the mulitplexin family (Oh et al. 1994A 
and B, Sasaki et al. 2002).  
 
1.5 Embryonic Stem Cells (ES-cells) 
 
The embryoid body as in vitro system gives the opportunity to observe comprehensively the 
endothelial differentiation program and it is therefore an adequate system to analyse the 
molecular mechanisms, which are involved in vasculogenesis and angiogenesis (Vittet et al. 
1996). Embryonic stem cells are non-transformed cell lines, which are extracted directly out 
of pluripotent foundation tissue of mice embryo, the epiblast (Brook and Gardner 1997, Evans 
and Kaufman 1981, Martin 1981). It has been shown that they have the potential to generate 
all embryonic cell lineages when they undergo differentiation (Smith 1992). ES-cells can be 
maintained in their pluripotential state if cultured in the presence of leukaemia inhibition 
factor (LIF), which inhibits their differentiation. When LIF is removed, ES cells 
spontaneously differentiate into cyst-like structure, termed embryoid bodies (EBs), which 
contain derivatives of the three primitive germ layers (Smith 1992). The appearance of blood 
island-like structures that consist out of immature hematopoietic cells surrounded by 
endothelial cells and the formation of vascular-like channels have been reported on the surface 
of cystic EBs, suggesting that ES-cells produce all factors which are necessary for the 
induction of vasculogenesis (Doetschman et al. 1985, Risau and Lemmon 1988, Wang et al. 
1992, Doetschman et al. 1993, Young et al. 1995). The aggregation of ES-cells induces the 
formation of several cell types (Bain et al. 1995, Okabe et al. 1996, Fraichard et al. 1995, 
Strubing et al. 1995). To receive EBs of equal size, which therefore are comparable, a defined 
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amount of ES-cells were taken to perform EBs by a cultivation technique called „hanging 
drop“ method (Fasseler et al. 1996) (fig. 2.1). After attachment, EBs begun to grow out 
centrifugal from the central cell accumulation. The area around the point of attachment shows 
strongest proliferation but low differentiation. Due to the centrifugal outgrowth in the 
periphery of EBs only a thin cell layer could be found, however with the strongest 
differentiation. By differentiation of pluripotent ES-cells inside of EBs several different cells 
types could be found, like endothelial cells (Wang et al. 1992, Keller 1995), muscle cells 
(Keller 1995, Drab et al. 1997), neuronal cells (Bain et al. 1995, Okabe et al. 1996, Fraichard 
et al. 1995, Strubing et al. 1995, Keller 1995), cardiac muscle cells (Wobus et al. 1991, 
Maltsev et al. 1994, Hescheler et al. 1997), keratinocytes (Bagutti et al. 1996), heamatopoetic 
cells (Keller 1995) and so on. During the formation of vascular structures in EBs several 
different endothelial specific marker appear, like PECAM-1 (Platelet Endothelial Cell 
Adhesion Molecule-1) (DeLisser et al. 1994), VE-(vascular endothelial)cadherin 
(Lampugnani et al. 1992) and growth factor receptors like Flk-1 (Yamaguchi et al. 1993, 
Oelrichs et al. 1993 and tie-1/tie-2 (Sato et al. 1993, Schnurch and Risau 1993). The 
expression pattern of endothelial specific markers, found in EBs, seems to be very similar to 
that of embryonic angio- and vasculogenesis (Baldwin et al. 1994, Yamaguchi et al. 1993, 
Sato et al. 1993, Breier et al. 1996, Dumont et al. 1995). 
 
1.6 Target of the Work 
 
The target of this work is to analyse the influence of the extracellular matrix derived factors 
endostatin and restin on the endothelial cell biology during vascular development. This 
examination should be performed by a model system of embryonic vessel development, the 
Embryoid Body (EB) as well as by a model system of regenerative neovascularisation, the 
physiological wound healing. The following questions should be answered: 
 
 
 Give the existence and distribution of binding sites for endostatin and restin, evidence 
for an anti-angiogenic influence in human urological tumours? 
 
 Are embryonic vessels accessible for endostatin and restin, do they express and 
accumulate these molecules and show binding sites for them? 
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 Do endostatin and restin influence the embryonic vessel development and the 
regenerative neovascularisation? 
 
 Is the heparin-binding site decisive for the effects of endostatin and restin? 
 
 Is the morphogenesis of vessels influenced by endostatin and restin? 
 
 Do this factors influence the endothelial signaltransduction? 
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2. Material and Methods  
 
2.1 Used chemicals and materials 
 
The following chemicals were obtained from Gibco BRL Gaithersburg: 
 
Dulbecco`s Modified Eagle Medium (DMEM) 
Foetal Calves Serum (FCS) 
L-Glutamin 
MEM (non-essential amino acids) 
Penicillin  
Streptomycin 
 
The following chemicals were obtained from Merck, Darmstadt, Germany: 
 
Boron acid (crystal/H3BO3) 
Di-Sodium-carbonate (Na2CO3) 
Di-Sodiumhydrogenphosphate-di-hydrate (Na2HPO4) 
EDTA (Ethylendinitroilotetraaceticacid/C10H14N2Na2O8) 
HEPES (N-[2-Hydroxyethyl]-piperazineN‘-(2-ethansulfonacid/C8H18N2O4S) 
Potassium-Chloride (KCl) 
Magnesium-Chloride (MgCl2) 
Sodium-Chloride (NaCl) 
Sodium-di-hydrogenphosphatemonohydrate (NaH2PO4) 
Sodium-hydrogen-carbonate (NaHCO3) 
Paraformaldehyd ((CH2O)n) 
Proteinase K 
Saccharine (C12H22O11) 
Tri-Sodium-Citrate (C6H5Na3O7) 
Tris (Trishydroxymethylaminomethan/C4H11NO3) 
Tween 20 
 
Chloroform (CHCl3) 
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Acetic acid (C2H4O2) 
Methanol (CH4O) 
 
The following materials were obtained from Sigma Aldrich, Taufkirchen, Germany: 
 
Acrylamid (C3H5NO) 
Ammoniumchlorid (NH4Cl) 
Amoniumpersulfat ((NH4)2S2O8) 
Bovine Serum Albumin (BSA) 
DAB (3-3‘Diaminobenzidin) 
DMSO (Dimethylsulfoxide/C2H6OS) 
DTT (Dithiothreitol) 
Gelatine 
Glycerin (C3H8O3) 
N’N‘-Methylenbisacrylamid (C7H10N2O2) 
Pipes (Piperazine-N,N‘-bis[2-ethanesulfonicacid]/C8H18N2O6S2) 
PMSF (Phenylmethylsulfonyl Fluoride/C7H7FO2S) 
Salmon Sperm DNA  
SDS (Sodium Dodecyl Sulfat/C12H25O4SNa) 
TEMED (N,N,N‘,N‘-Tetramethylenediamine/C6H16N2) 
Trypsin 
Yeast tRNA 
 
The following materials were obtained from Serva, Heidelberg, Germany: 
 
Bromphenolblue 
Mitomycin C 
PG 6000 (Polyethylen Glycol) 
Triton X-100 
 
Glycin (C2H5NO2)    Fulka Chemie AG, Buchs, Switzerland 
Formamid (CH3NO)    Fulka Chemie AG, Buchs, Switzerland 
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Coomassie Brilliant Blue R 250  BioRad Laboratories Munich, Germany 
 
Powdered milk (fatty free):   Glücksklee, Nestle, Germany 
 
Paraffin     Sherwood Medical (Paraplast Plus), Ireland 
 
Ethanol     Firm Hofmann, Düsseldorf, Germany 
 
The following materials were obtained from Falcon (Becton Dickinson), Heidelberg, Germany: 
 
Bacteriological tissue culture dishes (6 cm, 10 cm) 
Multiwellplates 
Centrifugation tubes 
 
The following equipment was obtained from Heraeus Instruments, Hanau, Germany: 
 
CO2-Incubator 
Lamina 
 
The following materials were obtained from BioRad Laboratories, Munich, Germany: 
 
Gel chamber 
PowerPac 300 
 
The following materials were obtained from B. Braun Biotech International, Melsungen, 
Germany: 
 
Micro-Dismembranator U 
Teflon-container 
Wolfram carbide-bead 
 
The following equipment was obtained from Zeiss, Oberkochen, Germany: 
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Deconvolution-Microscope, Axiovert 
Deconvolution-Software KS 400 3.0 
Fluorescence-Microscope, Axiophot 
 
Glass-Teflon-Homogenisator (Potter), IKA Laborwerke, Hannover, Germany 
 
Micro pipettes/Variopipettes  Eppendorf, Hamburg, Germany 
 
All aqueous solutions were prepared with distilled water from our own distiller Milli-RX 20 
from Millipore. 
 
Humane kidney, bladder and prostate tissue was obtained from „Urologischen Poliklinik“ 
University cologne. 
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2.2 Technical Basics  
 
2.2.1 Cell Culture  
For culturing cells were kept in a CO2-incubator surrounded by 5% CO2, 37°C and 95% 
humidity. All steps were taking place under sterile conditions, working under laminar air with 
sterilised materials and media. 
 
2.2.1.1 Stem Cell Culturing - the D3 cell line 
Mouse blastocyst-derived embryonic stem cells of the D3 cell line were maintained and 
cultured as described by Doetscham et al. 1985. The adherent grown cells were passaged all 2-
3 days to prevent a high cell density. A high density would have induced cell differentiation of 
the pluripotent embryonic stem cells. For passaging cells were washed wit 0.1 M PBS. Then 
cells were removed from the bottom by using the synthetic enzyme accutase, which has both 
characteristics of collagenase and trypsin, but in a mild manner. Cell suspension was 
centrifuged (5 min., 800 rpm, Heraeus Instruments, Labofuge 400, Hanau). After rejecting of 
supernatant the cell pellet was resuspended in DMEM-medium containing 15% FCS. After 
counting, 106 cells were plated in a 6 cm dish containing an inactivated feeder layer. The 
feeder layer provides the possibility to attach but more important the feeder cells produce 
leukaemia inhibition factor (LIF), which prevents the differentiation of embryonic stem cells. 
Stem cells medium was changed every day. 
 
0.1 M PBS:   81mM Di-Sodiumhydrogenphosphate-di-hydrate 
    19 mM Sodium-di-hydrogenphosphatmonohydrate 
    150 mM Sodium chloride, pH 7.4 
 
2.2.1.2 Preparation of mouse embryos to gain feeder cells 
To gain feeder cells 14-16 days pregnant mice were required. After killing, the uterus was cut 
out incubated in a petridish containing 0.1 M PBS. Then the embryos were preparated out of 
uterus and amniotic sac and incubated in fresh PBS. The thorax was opened; organs and the 
head were removed. The embryos were chopped up with scalpels in a dish with 0.1% trypsin 
and 0.02% EDTA. After homogenisation the cell suspension were filtered by using a sieve 
and distributed in petridishes (10 cm) containing DMEM-medium (10% FCS). 
 
The vascular development is modulated by endostatin and restin                                                               page 17 
2.2.1.3 Culturing of feeder cells 
Regularly feeder cells were passaged in the same way as described for the embryonic stem 
cells. Because of a lower metabolism rate, feeder cell passage and medium exchange was 
effected once a week. Feeder cells were cultured in DMEM-medium containing 10% FCS. 
 
2.2.1.4 Inactivation of feeder cells 
A layer of feeder cells constitutes the basis for embryonic stem cell growth. But to prevent 
their proliferation they were inactivated using the cell toxin mitomycin C. Adherent cells were 
treated for 2 hours (37°C) to prevent mitosis activity with a concentration of 10 µg/ml. After 
inactivation cells were washed three times with PBS and stored in DMEM-medium containing 
10% FCS till use. 
 
2.2.1.5 Preparation of hanging drops 
Embryonic stem cells were cultured in hanging drops (fig. 2.1) as described by Fassler et al 
1996. Therefore adherent cells were removed and pelleted before counting them. The volume 
of a hanging drop should grasp 20 µl. Every drop should contain 600 cells. After dilution of 
the cell suspension in an appropriate manner (DMEM+20% FCS) 50-60 drops were prepared 
on the inside of the lid. The bottom of this bacteriological petridish was filled with 10 ml PBS 
to prevent dry out of hanging drops. Then the lid was turned over and placed on the bottom of 
the dish. Within the following two days the single cells join together to form aggregates. 
 
2.2.1.6 Culturing of aggregates in suspension  
Two days after preparing hanging drops, the aggregates (embryoid bodies) were rinsed and 
cultured in suspension (10 ml DMEM-medium plus 15% FCS) for the next three days. For 
this purpose bacteriological (non-adhesive) petridishes were used. During these three days 
cells proliferate but do not differentiate.  
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Fig. 2.1 Culturing of embryonic stem cells.  
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2.2.1.7 Gelatine coating and plating of embryoid bodies 
Differentiation of the embryoid bodies (EBs) was induced by plating them on gelatine-coated 
cover slips. Therefore cover slips (12 mm diameter) were placed in every well of a 24-multi 
well plate and covered with 0.1% gelatine in 0.1 M PBS. Cover slips were incubated in 
gelatine solution over night. Before plating, the gelatine solution was removed, cover slips 
were air-dried and every well was filled with 1 ml medium (DMEM+15% FCS). Each 
embryoid body was taken out of suspension and placed in the middle of a gelatine-coated 
cover slip. Medium was changed the first time after three days to let EBs attach.  
 
2.2.1.8 Components of DMEM-medium 
 
DMEM-medium:   DMEM (Dulbecco’s Modified Eagle Medium) 
     50 U/ml Penicillin 
     50 U/ml Streptomycin  
     200 µM L-Glutanine 
     100 µM β–mercaptoethanol  
     1% MEM (non-essential amino acids) 
     15% or 20% Foetal Calves Serum (FCS, v/v) 
Before usage the foetal calves serum was heat inactivated for 30 min. at 56°C.  
 
2.2.2 Tissue Processing 
 
2.2.2.1 Fixation of Tissue 
Cells and tissue, received fresh from operation room, were chemically fixed by using 4% 
paraformaldehyde (4% PFA) in 0.1 M PBS. During fixation the NH2-groups of cellular and 
membrane proteins get connected by aldehyde bindings. The duration of fixation procedure 
depended on tissue size, due to the fact that PFA saturate tissue with a speed of 0.5 mm per 
hour. The tissue was then washed several times with 0.1 M PBS. For electron microscopy 
tissue was fixed in 2% paraformaldehyde/2% glutaraldehyde in 0.1 M cacodylate buffer pH 
7.2 over night. After washing in cacodylate buffer tissue was treated with 1% uranyl acetate.  
 
4% PFA    4% parformaldehyde, 0.1 M PBS, pH 7.4 
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0.1 M PBS:    81mM Di-Sodiumhydrogenphosphate-di-hydrate 
     19 mM Sodium-di-hydrogenphosphatmonohydrate 
     150 mM Sodium chloride, pH 7.4 
 
0.1 M Cacodylate-buffer   0.1 M Dimethylarsinicacid sodium salt trihydrate 
 
2.2.2.2 Tissue embedding for electron microscopy 
For the preparation of thin and ultrathin sections, tissues were fixed as described above. The 
sections were then incubated in 70% ethanol for 8 hours. Thereafter dehydration was 
performed in a series of graded ethanol, and specimens were then embedded in araldite. Thin 
sections of plastic embedded tissue were cut with a glass knife on a Reichert ultramicrotome 
(Reichert, Bensheim, Germany) and stained with methylene blue. Ultrathin sections (30-60 
nm) for electron microscopic observation were processed on the same microtome with a 
diamond knife and placed on copper grids. The transmission electron microscopy was 
performed with a Zeiss 902A electron microscope (Zeiss, Oberkochem, Germany). 
 
2.2.2.3 Tissue embedding in paraffin  
For paraffin embedding tissue must be dehydrated. Therefore tissue was incubated for 24 
hours in 30%, 50%, 70%, 90%, 96% ethanol and two times in 100% isopropanol. As inter 
medium chloroform was used for 24 hours. Thereafter tissue was incubated two times for 2-3 
hours and following over night in paraffin (60°C). At the end tissue was lined up in a block, 
filled with fresh paraffin before cooled down to solidify. For optimal cutting conditions the 
paraffin block was cooled. 
 
2.2.2.4 Tissue embedding for cryostat sections 
To perform cryostat sections the tissue was fixed and washed as described above. Thereafter 
tissue was incubated in tissue freezing medium (Jung, Nussloch, Germany) covered by tin foil 
and store in –80°C. Before cutting tissue was stored for 30 min. at –30°C. The cryostat 
temperature during cutting was –30°C. 
 
2.2.2.5 Shock freezing of tissue 
Tissue for SDS-PAGE and western blotting received freshly from operation room was directly 
incubated in fluid nitrogen and stored in –80°C. 
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2.2.3 Immunohistochemistry 
During the procedure of immunohistochemistry proteins and enzymes were specifically 
marked and detected by using corresponding antibodies. Immunohistochemistry with the 
following course is a standard procedure, however here only the principal will be described. 
The specific antibody choice and arrangement will be detailed individually for each 
experiment. 
 
2.2.3.1 Procedure of immunohistochemistry 
The permeabilisation of cells is an important point to facilitate the antibody binding to inner 
cell proteins. Therefore tissue sections and cells were incubated 10 min. with 0.25% Triton-X-
100 and 0.5 M ammonium chloride in 0.05 M TBS. The detergent Triton-X-100 permeabilises 
the cell membrane while ammonium chloride reacts with free aldehyde groups to prevent an 
unspecific binding of the antibody. Following the cells were washed with TBS (3 x 10 min.). 
To prevent unspecific bindings due to loading differences, sections and cells were incubated 
with 5% BSA in 0.05 M TBS. The following incubation with the primary antibody occurred 
over night at 4°C. After several washings the incubation with the corresponding secondary 
antibody lasted 1 hour at room temperature. If the secondary antibody was conjugated with 
biotin instead of the fluorochrom CY2 or CY3, an incubation with streptavidin-conjugated 
CY2 or CY3 followed. For light microscopic observation a development based on an 
enzymatic reaction was performed by using DAB-solution. Therefore a streptavidin 
horseradish-peroxidase-complex was used after incubation with the biotin-conjugated 
secondary antibody. The development with DAB was controlled under the light microscope. 
 
0.05 M TBS-buffer    50 mM Trishydroxymethylaminoethan (tris) 
      150 mM Sodium chloride, pH 7.6 
 
DAB-solution:     0.1 M PB, 1% DAB, 0.75% H2O2 
 
 
0.1 M PB:     81 mM Di-Sodiumhydrogenphosphate-di-hydrate, 
19 mM Sodium-di-
hydrogenphosphatemonohydrate, pH 7.4 
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2.3 Bladder, Kidney and Prostate Tissues  
 
Malignant and benign bladder tissue specimens were obtained from 12 patients. Eight patients 
underwent transurethral resection and four patients underwent radical cystectomy for bladder 
cancer (mean age 67.9 years, median 69 years). In final histological staging, there were two 
patients with stage pTaG1, four with pT1G2, two with pT1G3, three with pT2G2, and one 
with pT3G3. In this study, prostate samples from 24 patients were tested. Prostate biopsies 
were collected from 12 patients with prostate cancer (mean age 69.7 years, median 70 years) 
before they underwent external beam radiation and HDR brachytherapy. In this prostate 
cancer group there were three pT2G1 cases, eight pT2G2 cases and one pT2G3 case. Normal 
benign prostate tissue specimens from 12 further patients with benign disease (mean age 69.7 
years, median 70 years) served as controls. None of the prostate cancer patients in the first 
group had received preoperative hormonal therapy, radiation, or chemotherapy. The 21 
patients benign prostatic hyperplasia underwent suprapubic prostatectomy.  
Kidney tissues (malignant and benign) were obtained from twelve patients (average 63.8 
years, median 64 years). All patients underwent nephrectomy for kidney tumours. In final 
histological staging, there were three patients with stage pT2G2, four with pT1G2, two with 
pT2G3, and three with pT3G2. 
 
2.4 Animals 
 
Balb/c mice and B2D2F2 mice were obtained from the animal care facility of the Max-
Planck-Institute of Biochemistry, or from RCC (Füllinsdorf, Switzerland). They were housed 
and fed according to federal guidelines, and all procedures were approved by local authorities. 
 
2.5 Wounding and preparation of wound tissue 
 
Wounding and preparation of wound tissue was performed by Sabine Werner (Institute for 
cell biology, ETH-Zurich, Switzerland). Mice were anaesthetised with a single intreperitoneal 
injection of ketamine/xylazine. The hair on the animals’ back was cut and the skin was wiped 
with 70% ethanol. Four full-thickness excisional wounds (6 mm diameter, 3-4 mm apart, two 
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wounds on each side of the spinal cord) were generated on the back of each animal by 
excising skin and panniculus carnous as described by Munz et al. 1999. The wounds were 
allowed to dry to form a scab. Animals were killed at various time points after injury. 
Prepared wound tissue was fixed as described above.  
 
2.6 Different kinds of endostatin 
 
For the following experiments three different kinds of endostatin were used. Mouse-
endostatin M-ES(4), human endostatin (human ES(2)), restin, a proteolytic fragment of 
collagen XV as well as R158/R184/R270A (RA) a heparin binding mutant form of endostatin 
(A kindly gift of Dr. R. Timpl, MPI for biochemistry, Martinsried). This heparin binding 
mutant form of endostatin was described in detail before (Sasaki et al. 1999). The purification 
of recombinant mouse endostatin from transfected human kidney cells and a 
radioimmunoinhibition assay for quantitation have been described before (Sasaki et al. 1998). 
The extraction of tissue was performed as recently described (Miosge et al. 1999) 
 
2.7 Endostatin treatment of cells and mice 
 
Embryoid bodies (EBs) were treated with 50 ng/ml and 200 ng/ml endostatin, restin as well as 
the heparin mutant form of endostatin R158/R184/R270A (RA). 
Female Balb/c mice or B2D2F2 mice (12 weeks of age) were injected with 0.3 mg/kg s.c. 
murine endostatin, restin and R158/R184/R270A in 100 µl 0.9% saline/0.02M ammonium 
acetate pH 6.8. Control animals were injected with solvent alone. Injection was performed 
daily at 11:00 a.m. for 2 days before wounding, immediately after injury and for 5 consecutive 
days. Mice were killed at day 5 after wounding. 
 
2.8 Binding-Assay 
 
2.8.1 Biotinylation of endostatin 
The biotinylation of endostatin was performed as described previously by Friedl et al. 1997. 
Briefly, the protein endostatin, restin as well as the heparin mutant form of endostatin 
(R158/R184/R270A) were diluted in boron buffer (pH 8.8) up to a concentration of 1 mg/ml. 
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Biotin-X-NHS (MW 454.5, Calbiochem, Schwalbach, Germany) was dissolved in DMSO (1 
mg/ml). 12.5% (v/v) of the biotin solutions were incubated with the endostatin solution at 4°C 
for 4 hours. Subsequently, surplus biotin was removed by filtration against boron buffer. The 
efficiency of the biotinylation procedure was analysed by detecting endostatin and biotin-
conjugated endostatin through western blotting. 
 
Boron buffer:     10 mM Boron acid (crystal 150 mM  
Sodium Chloride, pH 8.8 
 
2.8.2 Fluoresceinisothiocyanat-(FITC-)conjugation of endostatin 
FITC (Isomer I, on Celite, Sigma, Chemical Company, St. Louis, MO, USA) mixed with 
silica gel (N-HR, Macherey Nagel Düren, Germany) 1:10 (w/w). The FITC/ silica gel-mixture 
was mixed with the endostatin solution 1:3 (w/v) and incubated for 25 min. at room 
temperature. Then the solution was centrifuged to pellet the silica gel (5 min. at 2000 rpm, 
Heraeus Instruments, Labofuge 400, Hanau, Germany). The supernatant was dialysed against 
sodium-carbonate/bicarbonate-buffer (pH 9.5) to remove surplus FITC.  
 
Sodium-carbonate/bicarbonate-buffer:  1 M sodium-hydrogen-carbonate 
1 M Di-sodium-carbonate, pH 9.5 
 
2.8.3 Western -Blot to examine the biotin-conjugation 
In order to examine the biotinylation of endostatin a western-blot was performed as described 
below. The slots were filled either with biotin-conjugated endostatin or non-conjugated 
endostatin. One half of the blot was treated with a rabbit-anti-endostatin-antibody (polyclonal, 
1:2000, a kind gift of Dr. R. Timpl MPI for biochemistry, Martinsried), the other half was 
treated with streptavidin-biotinylated-horseradish-peroxidase-complex (Amersham, LIFE 
SCIENCE, Little Chalfont, Buckinghamshire, England, 1:200). Streptavidin binds to biotin. 
Afterward the blot was developed with DAB-solution. 
 
DAB-solution:    0.1 M PB, 1% DAB, 0.75% H2O2 
 
0.1 M PB:     81 mM Di-Sodiumhydrogenphosphate-di-hydrate, 
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19 mM Sodium-di-hydrogenphosphatemono 
hydrate, pH 7.4 
 
2.8.4 Incubation with biotin-conjugated endostatin 
Embryoid bodies and tissue slices were incubated over night at 4°C with 50 ng/ml 
biotinylated endostatin, biotinylated restin and biotinylated heparin mutant endostatin 
respectively in 0.05 M TBS. After several washings bounded biotinylated endostatin was 
detected by using streptavidin conjugated CY3. Following an immunohistochemical detection 
of endothelial cells and vessels was performed as described below.  
 
2.8.5 Ultrastructural Cytochemistry 
Tumour tissues were fixed immediately after surgical removal in a fixative, containing freshly 
prepared 4% paraformaldehyde, in 0.1 M phosphate buffered saline (PBS, pH 7.4). After 4 
hours of immersion fixation, tissue sections of 50-70 µm thickness were prepared on a 
vibratome (Leica VT 1000) and washed carefully in PBS. The endostatin-biotin binding was 
conducted for 12 hours at 4°C in 0.05 M tris buffered saline (TBS) followed by five washing 
cycles in TBS. Finally, the biotin-detection was carried out with Extravidin, coupled to 15 nm 
colloidal gold (Sigma-Aldrich, Taufkirchen, Germany) in TBS containing 0.8% bovine serum 
albumin (BSA) overnight at 4°C. After rinsing in TBS, the incubated tissue sections were 
stabilised with 2% glutaraldehyde in cacodylate buffer and post-fixed with osmiumtetroxide. 
After „en bloc„ counter staining with 1% uranylic acetate, the samples were dehydrated with 
ethanol and embedded flat in Araldite epoxy resin, using propyleneoxide as intermedium. 
Thin sections of silver-grey interference colour were cut on an ultramicrotome (Reichert 
Ultracut UCT) and collected on 150 mesh formvar coated copper grids, which were not 
further stained in order to intercept the gold signal in the electron microscopy. Also thin 
sections were collected on 100 mesh formvar coated nickel grids for preparing a pre-
immunogold staining. Sections were washed several times in TBS, permeabelized with 5% 
HCl, blocked with 1% powdered milk and 0.1% Tween-20 in TBS for 30 min. at room 
temperature and incubated with Extravidin coupled with 15 nm colloidal gold (1:20, Zymed 
Laboratories, INC., San Francisco, CA, USA) for 2h at room temperature. Gold staining, to 
detect bound, biotinylated endostatin was stabilised with 2% glutaraldehyde for 10 min. and 
counter stained with uranylic acetate for 20 min. The sections were evaluated with a Zeiss EM 
902A electron microscope at 80 kV. 
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2.9 Detection of endothelial cells and vessels 
 
The immunohistochemical procedure was performed as described above. To mark endothelial 
cells and vessel like structures the antibody rat anti-mouse-PECAM-1 (CD31) was used 
(1:800, mAb, Pharmingen, San Diego, CA, USA). The relevant secondary antibody was sheep 
anti-rat Ig biotinylated (1:400, Amersham, LIFE SCIENCE, Little Chalfont, 
Buckinghamshire, England). This biotinylated antibody was detected with Extravidin 
conjugated CY 3 (1:1000, Sigma Chemicals, St. Louis, MO, USA; absorption 552 nm, 
emission 565 nm) or Alexa Fluor™ conjugated 488 (Mo Bi Tec, Göttingen), a fluorochrom 
that absorbs blue light with a wavelength of 495 nm and emit green light with a wavelength of 
519 nm. For evaluation every vessel-like, PECAM-positive structure of at least six EBs from 
endostatin treated as well as untreated were counted. 
 
2.10 Proliferation-Assay 
 
In order to analyse the influence of endostatin on the proliferation an immunohistochemistry 
was performed with an antibody against Ki67 (Kosco-Vilbois et al. 1997, Traut et al. 1998, 
Heidebrecht et al. 1996). Ki67 is active in all cell cycles phases (G1, S, G2 and mitosis). In 
resting cells (G0-phase) Ki67 lacks. After identifying the endothelial cells as described, 
proliferating cells were detected with the primary antibody rabbit anti-mouse-Ki67 (1:150, 
pAb, Dianova, Hamburg, Germany). The relevant secondary antibody was goat anti-rabbit 
conjugated CY2 (1:200, Dianova, Hamburg, Germany; absorption 495 nm, emission 519 nm). 
For utilisation proliferating endothelial cells of vessel-like structures were counted (n=6) with 
an Axiophot fluorescence microscope (Zeiss, Oberkochen, Germany) by using a fluorescent 
double filter. 
 
2.11 BrdU cell proliferation 
 
Proliferation of EBs cultured with and without endostatin, restin as well as the heparin mutant 
form (R158/R184/R270A) were analysed by using a BrdU-Assay (n=4) (for detail see Bloch 
et al. 1997). 
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2.12 Apoptosis-Assay 
 
The apoptotic effect of endostatin (O’Reilly et al. 1997, Dhanabal et al. 1999A) was analysed 
immunohistochemically focusing on caspase-3 and anti-Poly(ADP-
Ribose)Polymeras(PARP)p85-fragment (Ellis et al. 1991, Steller 1995, Burek and Oppenheim 
1996, Johnson et al. 1996, Cohen et al. 1992, Arends et al. 1990, Trucco et al. 1998, Smulson 
et al. 1998, Duriez and Shah 1997, Simbulan-Rosenthal et al. 1998, Saldeen and Welsh 1998, 
Patel et al. 1996, Alnemri et al. 1996, Fujita and Tsuruo 1998). Apoptotic cells were detected 
with a rabbit anti-active-caspase 3 antibody (1:500, pAb, Pharmingen, San Diego, CA, USA) 
or a rabbit anti-Poly(ADP-Ribose)Polymeras (PARP) antibody p85 fragment (1:250, pAb, 
Promega, Madison, WI, USA). The secondary antibody goat anti-rabbit conjugated CY 2 was 
used and the number of apoptotic endothelial cells were counted under a fluorescence 
microscope (n=6).  
 
2.13 Migration-Assay 
 
Migration-Assays were performed in a modified Boyden-Chamber by using a 24-well HTS 
Fluoro Blok TM insert system (fig. 2.2) (Falcon Becton Dickinson GmbH, Heidelberg, 
Germany). This insert is made out of a polyethylene membrane with 8.0 µm pores and it 
blocks >99% of the light transmission in a wavelength region from 490 till 700 nm. Inserts 
were coated with 0.1% gelatine solution (in 0.1 M PBS) for 1 hour. EBs (5+12) were 
dissociated with Accutase (PAA Laboratories GmbH, Linz, Austria). Afterwards 104 single 
cells were put on top of an insert and incubated for 8 hours in DMEM with 15% FCS for 
control or additionally with endostatin, restin as well as the heparin mutant form 
(R158/R184/R270A) in a concentration of 50 and 200 ng/ml. Then, cells were fixed and 
immunohistochemically stained with PECAM-1 antibody. Afterwards, the membrane was cut 
out of the insert and covered in DAPI mounting medium (4´,6-diamidino-2-phenyl-indole, 
Vectashield, Vector Laboratories, Burlingame, CA, USA; absorption 360 nm, emission 460 
nm) between two thin cover slips. The total number of migrated cells was counted as well as 
the number of migrated endothelial cells (n=6). It was not possible to perform a chemotaxis 
chamber with different gradient of endostatin as described by Dhanabal et al. 1999B and C 
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and Yamaguchi et al. 1999 because of its high diffusion rate trough the chamber. Difference 
in concentration would be balanced over a period of a few minutes.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.2 Migration. Schematic depiction of a modified Boyden chamber 
 
2.14 Signaltransduction  
 
2.14.1Treatments 
Embryoid bodies (EBs) were treated with 8bromo-cGMP (5 x 10-4M, Sigma, Deisenhofen, 
Germany) for immunohistochemical analysis and for vital microscopy as well as with ODQ 
(10-6M, Alexis, Grünberg, Germany), NONOate (10-5M, Alexis, Grünberg, Germany), 
PD98059 (5 x 10-4M, Calbiochem, Darmstadt, Germany) and with PP2A inhibitor, ocadaic 
acid (10-10M, Calbiochem, Schwalbach, Germany) for immunohistochemical analysis. 
 
2.14.2 Immunohistochemistry 
The primary antibodies anti-active ERK1/2-kinase (1:400, m mAb, Sigma, Sant Louis, USA), 
anti sGC (1:1000, rb pAb, Alexis Biochemicals, Grünberg, Germany), anti-active AKT-kinase 
(1:500, rb pAb, upstate, Hamburg, Germany). anti-ERK1/2-kinase (1:400,rb, pAb, upstate, 
Hamburg, Germany), anti-AKT-kinase (1:500, rb, pAb, upstate, Hamburg, Germany), anti-
cGMP (1:600, rb, pAb, Biogenesis, Poole, England), anti-iNOS (1:1000, rb, pAb, Biomol, 
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Hamburg, Germany), anti-bNOS (1:1000, mouse, mAb, Transduction, Lexington USA), anti-
Nitrotyrosine (1:300, mouse, mAb, Calbiochem, Darmstadt, Germany), anti-eNOS (1:1500, 
rb, pAb, Biomol, Hamburg, Germany), anti-Flk-1 (1:200, rb, pAb, Santa Cruze, California, 
USA), anti-Flt-1 (1:200, rb, pAb, Santa Cruze, California, USA), anti-VEGF (1:200, rb, pAb, 
Santa Cruze, California, USA). Secondary antibodies, goat-anti-rabbit and goat-anti-mouse 
conjugated with biotin (1:400, Dako, Hamburg, Germany) were used in a dilution of 1:400 in 
0.8% BSA for slices. Sheep-anti-rat Ig biotinylated (1:400, Amersham, LIFE SCIENCE, Little 
Chalfont, Buckinghamshire, England), goat-anti-rabbit Ig conjugated CY2, goat-anti-mouse Ig 
conjugated CY2 (1:200, Dianova, Hamburg, Germany, absorption 495 nm, emission 519 nm) 
as well as streptavidin-conjugated CY3 (1:1500, Amersham, LIFE SCIENCE, Little Chalfont, 
Buckinghamshire, England, absorption 552 nm, emission 565 nm) were used for cells. For 
utilisation an Axiophot fluorescence microscope (Zeiss, Oberkochen, Germany) was 
employed for light and fluorescence (filter: CY3: absorb.: 552 nm and emiss.: 565 nm; CY2 
absorb.: 495 nm and emiss.: 519 nm). 
 
2.15 Magnet associated cell sorting (MACS) 
 
Differentiated embryonic stem cells, cultured as described above, in the age of 5+7 EBs were 
dissociated with Accutase (PAA Laboratories GmbH, Linz, Austria). The single cell solution 
was washed with medium and incubated with the endothelial specific marker rat anti-mouse-
PECAM-1 (CD31) (1:800, mAb, Pharmingen, San Diego, CA, USA) for 30 minutes at 37°C, 
5% CO2. Cells were washed with MACS-buffer (0.5% BSA and 2 mM EDTA in 0.1 M PBS) 
and incubated with the secondary antibody, which was conjugated with goat anti-rat IgG 
micro beads (1:4, Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) for 15 minutes at 6-
8°C. After washing cells were MACS sorted by using a mini-MACS system with MS 
separation columns (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany). The positive 
fraction gets cultured on gelatine-coated dishes. After 2-3 weeks the endothelial cells get 
passaged for the first time and afterwards once till twice a week. Cells were used till passage 
8. MACS sorted endothelial cells (passage 3) were cultured with and without endostatin in a 
concentration of 50 ng/ml and immunohistochemical stained as described above.  
 
2.15.1 Purity of MACS-sorted endothelial cells 
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The purity of cells was tested with dil-Ac-LDL (Paesel+Lorei GmbH & Co, Hanau, 
Germany). The MACS-sorted endothelial cells were tested for several endothelial specific 
markers. They were positive for PECAM-1, flk-1, flt-1, VEGF, Lectin, VE-Cadherin, eNOS 
and occasionally positive for CD34 and CD133. After staining with dil-Ac-LDL as well as 
PECAM-1/Hoechst Dey (Sigma Chemicals, St. Louis, MO, USA) the purity of the MACS-
sorted endothelial cells was determined and amounted 89% (data not shown). 
 
2.16 The live reporter gene EGFP under control of the PECAM-1 promoter 
 
2.16.1 Vectors 
The plasmid GL3-4500/+196 containing the human PECAM-1 promoter fragment was kindly 
provided by Dr. P.J. Newman (Gumina et al. 1997). The pEGFP vector construct (BD-
Biosciences-Clontech, Heidelberg, Germany), which lacks eukaryotic promoter and enhancer 
sequences, was used as backbone expression vector. To generate the PECAM-1-
promoter/EGFP construct, GL3-4500/+196 –was digested with PstI, and the resulting 4.6-kb 
PstI fragment of the human PECAM-1 promoter (-4500/+196) was subcloned into EGFP. The 
resulting vector GL3-4500/+196-(PECAM-1)-EGFP was used for electroporation of ES cells 
of the D3 line (Doetschman et al. 1995, Kolossov et al. 1998, Wobus et al. 1991). 
 
2.16.2 Electroporation and selection procedure 
GL3-4500/+196-(PECAM-1)-EGFP was digested by Eco47III restrictase in order to linearize 
the vector. 30µg of the Eco47III linearized vector was used for electroporation (240V/500µF) 
of 5 x 106 ES cells. Then, G418 selection was performed according to standard protocols 
(Kolossov et al. 1998). Embryoid bodies were generated using the hanging drop technique 
(Fasseler et al. 1996). Hanging drops were established by plating a suspension of ES cells in 
final concentration of 2-2.5 x 104 cells/ml in 20 µl (400-500 cells) of DMEM+20% of foetal 
calf serum on the lids of bacterial dishes. After incubation at 37°C, 5% CO2 for 2 days the 
growing embryoid bodies were washed with 10 ml DMEM + 20% FCS into bacterial dishes 
and incubated for further 3 days. Then, embryoid bodies were plated separately on gelatine 
pre-treated 24 well plates. During all stages of development growing embryoid bodies were 
monitored under the fluorescent microscope using a FITC filter set (Zeiss, Jena, Germany). 
Consistent EGFP expression restricted to vessel-like structures was detected in 7 clones out of 
20 clones investigated. For the present study were used preferentially two of these clones. 
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2.17 Vital microscopy or Time-lapse microscopy 
 
In order to live monitor early stages of vasculogenesis, ES-cell derived vessel like structures 
were continuously observed up to 4 days (Kazemi et al. 2002). For that purpose an inverted 
microscope (Axiovert 100, Zeiss, Jena, Germany) was equipped with a computer controlled 
motorised stage (Merzhaeuser, Nikon, Germany), and a temperature/CO2 controlled chamber 
(Buehler, Nikon). Using alternate transmission- and fluorescent pictures (conventional 100 W 
halogen lamp) were recorded at 30 min intervals using a FITC filter set as well as an oil-
immersion objective 40x (Plan-Neofluar, Zeiss). Images were acquired using a colour video 
camera (Sony, DXC 950P, AVT Horn, Tuebingen, Germany) digitised on-line via a video 
frame grabber card (Matrox Corona, Nikon) and the Lucia software (Nikon). Enhanced 
fluorescence was achieved by the employment of a video-based buffer device (Sony MPU-
F100P, AVT Horn) and the integration mode of the camera (integration of 5 to 10 pictures, 
respectively). The development of embryonic stem cell derived endothelial cells and vessels 
cultured in DMEM medium (20% FCS) was compared to differentiation influenced by 
endostatin (100 ng/ml). 
 
2.18 Deconvolution 
 
2.18.1 General description of the deconvolution method  
 
2.18.1.1 The 3D-image stack 
The prerequisite for a 3-dimensional analysis of an object is the data recording of each of the 
three dimensions (x, y, z). This is possible recording 2-dimensional pictures with a 
simultaneous focussing through the object. For this purpose every focused layer have a 
constant distance. The result is a stack of 2-dimensional pictures (Fig. 2.3), which contain the 
whole 3-dimensional information. For this a motorised focus mechanism is required. 
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Fig. 2.3 Schematic depiction of a stack of pictures 
 
2.18.1.2 Physical Background 
In case of a fluorescent microscopic observation the object is fluorescent in a defined scale. 
During observation the fluorescent signal of the object passes the „optical path“ of the 
microscope while a line of optical components, like lenses, mirrors and prism appears before 
it reaches the corresponding sensor, like the retina or the camera. When the objective light 
signal passes the microscope it changes depending on different parameters with the result that 
the received representation of the object does not correspond to the original. This is not only 
linked to the „optical path“. The fact that fluorescent light is a poly-chromatical light and that 
each component of this poly-chromatical light is positioned on another focus level, leads to 
the fenomenous of light scattering. The result is a blurred representation of the original 
structure. In physical description, this means that during the process of representation the light 
signal gets „convoluted“ by the „Point-Spread-Function“ of the optical system. This 
„convolution“ generates relatively low problems in the case of a 2-dimensional representation 
of an object during lateral (xy-)observation. However upon 3-dimensional representation of an 
object the axial (z-)observation results in significant changes in comparison with the original 
form. The effect of this „convolution“ can be represented for objects with a known form, for 
which usually fluorescent beads with a known diameter were used. In lateral xy-sectional 
plane the representation shows a round but slight distorted form (fig. 2.4 A). However in axial 
xz-sectional plane it is difficult to recognise the form of a bead (fig. 2.4 B). The representation 
shows that the bead is strongly distorted in z-plane, what makes clear that artefacts were 
generated during a 3D-representation of an object what results in a form, which does not 
correspond to the original form. 
 
2.18.1.3 Inversion of the representation process 
With the help of mathematical methods the process, which leads to degeneration of the 
representation, can be calculated. The result is an approximately reconstruction of the original 
object. The documented stack gets „deconvoluted“ by employing the known „Point-Spread-
Function“. The result of the „deconvolution“ is a new stack that shows the object in its 
original form (fig. 2.4 C and D). This process is complex and demands theoretical 
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assumptions about the conditions of the optical systems. As theoretical assumptions represent 
an approach, the 3D-deconvolution is an approximation to the real form of the object. 
 
A B
C D
 
Fig. 2.4: Fluorescent bead to represent and calculate the „Point-Spread-Function“ of an optical system. (A) 
Fluorescent bead before deconvolution is represented. The presentation occurs in xy-orientation. The round form 
of this bead is observable. (B) Fluorescent bead before deconvolution in xz-orientation. The beat is strongly 
distorted. (C) The fluorescent bead after deconvolution in xy-orientation shows a clear round form. (D) After 
deconvolution the bead is rather less distorted in xz-orientation. 
 
2.18.2 3D-Deconvolution of PECAM-positive vessels 
Deconvolution microscopy was used as a method to prove if there are morphological 
differences between PECAM-positive vessel like structures in Embryoid bodies when treated 
with and without endostatin. This method was prepared as described by Bohle et al. 2001. An 
inverted Zeiss Axiovert 100 M with a Zeiss 63 Planapochromat oil immersion-objective was 
used. Bandpass filter sets for CY 2 and CY 3 (AHF) without overlap in the fluorescence 
emission spectrum as well as the commercial software package KS 400 from Zeiss were used. 
Each specimen was acquired as an image stack with 64 planes. The distance of the image 
planes were set to 100 nm to assure proper oversampling of the optical resolution for the 
subsequent iterative deconvolution process. Both, theoretical point-spread functions based on 
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microscope and specimen data and measured point-spread functions (PSF) calculated from 
fluorescent beads with a diameter of 1µm (Molecular Probes, T-14792) were used. The 
conjugated gradient maximum likelihood deconvolution algorithm with 60 iterations was 
performed on the image stacks. Output intensities were scaled between grey value 0 and 255. 
Generally theoretical and measured point-spread functions generated comparable results with 
slightly higher resolution in the resulting images by using the measured PSFs. Afterwards a 3-
dimensional reconstruction of the object was performed by cutting the vessel like structure in 
diagonal direction. This facilitates to look into the vessel lumen. 
 
2.19 Immuno-Blot (Western-Blot) 
 
2.19.1 Homogenisation of tissue 
For homogenisation urological tissues as well as mouse embryos in the age of E 10.5, E 13.5, 
E 15.5 and E 18.5 were incubated in fluid nitrogen directly after preparation. The frozen state 
of the tissue facilitated to smash bigger tissue pieces to small ones. The small tissue fragments 
were crushed afterwards with a wolfram carbide bead (5 mm) in a Teflon container by using a 
micro-dismembranator (1600 beats/min.) for 2 min. During this procedure the tissue pieces 
were crushed to powder. Following the powder was added with protease inhibitor containing 
preparation buffer and potted to a homogeny mass. After addition of freezing buffer, the 
homogeny probes were centrifuged 20 min. at 8000 rpm (4°C); the supernatant was used for a 
Bradford assay (Bradford 1976). 
 
Preparation buffer:  240 mM Saccharine, 1 mM PMSF, 20 mM PIPES, 
    10 mM EDTA, 50 mM Sodiumhydrogenphosphate, pH 7.4 
 
Freezing buffer:  400 mM Saccharine, 5 mM HEPES, 5 mM Tris, 
    10 mM EDTA, 50 mM Sodiumhydrogenphosphate, pH 7.2 
 
2.19.2 Bradford-Assay 
The determination of the protein concentration was performed according to Bradford with 
Coomassie Brilliant Blue. After a dilution line with bovine serum albumin (BSA) a calibration 
curve was drawn up. After adding Bradford reagent (BioRad Laboratories GmbH, Munich, 
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Germany) probes were measured in a spectrophotometer DU 650 (Beckman, Munich, 
Germany) with a wavelength of 595 nm. 
 
2.19.3 SDS-PAGE 
The electrophoresis was prepared under denaturing conditions in a modified way according to 
Laemmli 1970. Gels with a size of 7x10 cm and 0.5 mm thickness include stacking gel and 
running gel. Gels were vertically fit in a flat gel chamber. The protein containing homogenate 
was used in a total concentration of 40 µg/ml, taken in SDS-probe buffer, denatured 5 min. at 
95°C and centrifuged (6400 rpm, neo Lab-Micro-Zentrifuge, neo Lab Heidelberg, Germany). 
The protein mixture were pipetted with a Hamilton syringe (Hamilton Bonaduz AG, 
Switzerland) in the slots. A protein standard of Sigma (Sigma, St. Louis, MO, USA; see 
below) was used as molecular weight marker. During electrophoresis 70 V / 16 mA were used 
per gel until the running front (Bromphenolblue) reached the running gel, than 100 V / 24 mA. 
Following the gel was stained with Coomassie-Blue or used for immunoblot (Western-Blot). 
 
Assembly of gels: 
     running gel (13.5% Acrylamid)  stacking gel 
 
1.5 M Tris/HCl pH 8.8  1.5 ml 
0.5 M Tris/HCl pH 6.8       0.5 ml 
Acrylamid solution    2.7 ml     0.34 ml 
10 % SDS    60 µl     20 µl 
10 % Amonium persulfat  40 µl     40 µl 
TEMED    3 µl     2 µl 
H2O     1.7 ml     1.1 ml 
 
Electrode buffer:  25 mM Tris (pH 8.3), 192 mM Glycin, 0.1% SDS 
 
SDS-Probe buffer:  200 mM Tris/HCl, 50 % Glycerin, 6.4% SDS,  
4% β-Mercaptoethanol, 0.0052% Bromphenolblue, (pH 7.2) 
 
Acrylamid solution:  30% Acrylamid, 0.75% N’N‘-Methylenbisacrylamid 
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Molecular weight marker (Sigma): HMW-marker proteins  molecular weight  
          (kDa) 
 
     Myosin    205 
     β-Galactosidase   116 
     Phosphorylase b   97.4 
     Albumin Bovine   66 
     Albumin Egg    45 
     Carbonic Anhydrase   29 
 
2.19.4 Coomassie-blue-(CB-)staining of protein gels 
The coomassie staining was prepared in a modified way according to Meyer and Lamberts 
1965 in which methanol was replaced by ethanol. After electrophoresis the gel was incubated 
for 30 min. in CB-staining solution and following incubated in CB-destaining solution until 
the background was colourless. The gels were scanned for documentation. 
 
 
CB-destain solution :   25% ethanol, 5% acetic acid, 70% H2O  
 
CB-staining solution:   0.2% Coomasie Brilliant Blue R 250 in CB-destain 
solution  
 
2.19.5 Transfer of proteins on a PVDF-membrane  
The transfer of electrophoretic separated proteins on a PVDF-membrane (BioRad, 0.2 micron) 
was carried out in a semi-dry-procedure with a „SemyDryBlotter II„ (KEMENTEC, 
Copenhagen, Denmark). The SDS-gel was equilibrated after electrophoresis for 15 min. in 
cathode buffer. Four layers of filter paper were equilibrated in cathode buffer, two layers in 
anode buffer I and one layer in anode buffer II. The membrane was washed and activated in 
methanol and equilibrated in anode buffer II. Afterwards the following transfer unity was built 
up between the two electrodes: 
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Cathode 
four layers filter paper in cathode buffer 
SDS-gel (equilibrated in Cathode buffer) 
membrane (in equilibrated in anode buffer II) 
one layers filter paper in anode buffer II 
two layers filter paper in anode buffer I 
Anode 
 
A voltage 170 mA was used for 1 hour for blotting. Afterwards the blot-gel was stained with 
Coomassie to control the transfer. 
 
 
Cathode buffer:  25 mM Tris, 40 mM Glycin, 20% methanol, pH 9.4 
Anode buffer I:  300 mM Tris, 20% methanol, pH 10.4 
Anode buffer II:  25 mM Tris, 20% methanol, pH 10.4 
 
2.19.6 Immunological Detection 
 
After the electron transfer of proteins, the PVDF-membrane was blocked for 1 hour at room 
temperature or over night at 4°C in washing buffer I containing 1% powdered milk and 
following washed three times for 15 min. in washing buffer I. Thereafter the incubation with 
the primary antibody rabbit-anti-endostatin (polyclonal, 1:2000, a kind gift of R. Timpl MPI 
for biochemistry, Martinsried) in washing buffer I followed (over night at 4°C). After washing 
(three times for 15 min.) with wash buffer I the incubation followed with the secondary 
antibody swine-anti-rabbit-conjugated-horseradish-peroxidase (Dako, Glostrup, Denmark, 
1:200) in washing buffer I with 0.1% powdered milk for 1 hour at room temperature. The 
membrane was washed three times for 15 min. with washing buffer II and incubated for 
detection in DAB-solution (3-3‘Diaminobenzidin). 
 
Washing buffer I: 25 mM Tris/HCl, 137 mM Sodium Chloride, 3 mM Potassium 
Chloride, 0.5% Tween 20, (pH 7.8) 
 
Washing buffer II:  correspond washing buffer I with 0.05% Tween 20 
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DAB-solution:  0.1 M PB, 1% DAB, 0.75% H2O2 
 
0.1 M PB:   81 mM Di-Sodiumhydrogenphosphate-di-hydrate, 
    19 mM Sodium-di-hydrogenphosphatemonohydrate, pH 7.4 
 
2.20 In situ-Hybridisation 
 
The usage of in situ-Hybridisation should give an inside in the expression pattern of 
endostatin in urological tumours and mouse embryos as well as regeneration during 
physiological wound healing. 
 
2.20.1 Preparation of the endostatin cDNA-sonde 
The vector pUC18 containing the sequence for establishing an endostatin cDNA-sonde (fig. 
2.5) was a kind gift of Dr. R. Timpl MPI for biochemistry Martinsried.  
 
 
 
 
 
 
 
Fig. 2.5: Human α1(XVIII)ES/pUC18. The PCR-fragment with a size of 0.55 kb contained a NheI- and a XhoI-
restriction side and was added in the with SamI cut pUC18-vector. 
 
The necessary sequence was cut with the restriction enzymes Xho I and Nhe I (Pharmacia 
Biotech, CA, USA) with the following assembly: 
 
15 µl DNA (1,5µg/µl, α1-human-endostatin in pUC-vector) 
3 µl 10x buffer 
2 µl Nhe I (8 U/µl) 
2 µl Xho I (10 U/µl) 
8 µl H2O 
30 µl  
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This solution was incubated over night at 37°C. After separation on a 1% agarose gel a 550 bp 
big fragment was received. The concentration of DNA was determined by using λ-DNA (New 
England Biolabs, Schwalbach/Taunus, Germany) in a further electrophoresis. The received 
DNA-band was cut out of the gel. Isolation of DNA occurred with a kit as described in 
manufacturers’ instructions (QIAEX II Gel Extraction Kit, Qiagen, Hilden, Germany). By 
using a DIG-DNA-Labelling-Kit digoxigenin was bound via alkali labile ester binding to the 
nucleotides. The digoxigenin labelling of DNA was executed also as described by 
manufacturers’ instructions (DIG-DNA-Labeling-Kit, Boehringer Mannheim, Germany). The 
DNA-sonde was stored at -20°C. 
 
2.20.2 ProteinaseK-Treatment and Pre-hybridisation 
After deparaffinisation, slices were washed in PBS/MgCl2 buffer. The proteinaseK-buffer was 
warmed up to 37°C and was mixed with proteinaseK (10 µg/ml). The tissue was incubated for 
10 min. at 37 °C. The reaction was stopped by washing in PBS/MgCl2 (5 min., room 
temperature) before the probes were equilibrated in Glycin/Tris-Puffer (10 min., RT). For pre-
hybridisation the pre-hybridisation solution was warmed up to 55°C and the tissue was 
incubated for 1 hour at 55°C. 
 
PBS/MgCl2 buffer:  PBS, 1 mM Mg/Cl2 
 
ProteinaseK-buffer:  0.5 M Tris/HCl, 0.1 M EDTA, 0.1 M Sodium Chloride 
 
Glycin/Tris-buffer:  0.1 M Glycin, 0.2 M Tris/HCl, pH 7.4 
 
Pre-hybridisation solution: 2 x SSC (0.3 M Sodium Chloride, 30 mM tri-Sodium-Citrate, 
pH 7.0), 50 % Formamid, 10 µg/ml Salmon Sperm DNA  
 
 
2.20.3 Preparation of cDNA-sonde and Hybridisation 
For preparation of the sonde 5% of cDNA (endostatin-sonde, v/v), 45% hybridisation solution 
(v/v) and 50 % formamid (v/v) were denatured for 5-15 min. at 95°C and incubated on ice for 
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3 min. The tissue was incubated in this mixture over night at 55°C. After washing at 55°C the 
tissue was incubated for 1 min. in buffer I. 
 
Hybridisation solution: PEG 6000, 5 M Sodium Chloride, 1M MgCl2, 1 M Pipes, 0.2 M 
EDTA, 1 M DTT, 10 mg/ml Salmon Sperm DNA, 10x 
Denhardt, 5 mg/ml Yeast tRNA (10:12:1:1:0.5:1:1:1:0.5) 
 
Wash buffer: 2 X SSC (0.3 M Sodium Chloride, 30 mM tri-Sodium-Citrate 
pH 7.0), 50 % Formamid 
 
Buffer I:   0.1 M Tris/HCl, 0.15 M Sodium Chloride 
 
2.20.4 Blocking and Detection 
For blocking a Boehringer-Blocking-Mix (10 mg/ml, Boehringer Mannheim, Germany) was 
used together with FCS and buffer I (30 min. at room temperature). Thereafter the incubation 
with an anti-DIG-antibody-conjugate-AP (1:100, in buffer I + FCS, Boehringer Mannheim, 
Germany) lasted for 30 min. at room temperature. After three washing steps with buffer I 
slices were incubated in buffer III (2 min., room temperature). For detection 0.35% 5-Bromo-
4-Chloro-3-Indolyl-Phosphate and 0.45% 4-Nitro-blue-tetrasodium-chloride (Boehringer 
Mannheim, Germany) was used. The detection was controlled under the microscope and 
stopped with Tris/EDTA-buffer.  
 
Buffer III:   0.1 M Tris/HCl, 0.1 M Sodium Chloride, 50 mM MgCl2  
 
Tris/EDTA-buffer:  8 mM Tris/HCl, 0.8 mM EDTA 
 
2.21 RT in situ-PCR 
 
After fixation with 4% PFA (in 0.1 M PBS, pH 7.4, 30 min., room temperature), cells were 
washed with PBS/MgCl2. Endogene peroxidase was blocked with 80% MeOH/2% H2O2 for 
20 min. For digestion 10 mg/ml Proteinase-K was used in Proteinase-K-buffer (10 min., 
37°C). To stop the reaction, cells were washed with PBS/MgCl2 and equilibrated in 0.1 
Glycin/0.2 M Tris-HCl, pH 7.4. For amplification a „C. therm Polymerase: One Step-RT-PCR 
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system“ (Roche Diagnostics, Mannheim, Germany) was used as described by the 
manufacturer. For amplification (thermocycler: MWG-Biotech AG, Ebersberg, Germany) of 
sGCalpha1 the following sequences were used: biotin 5’>CTC CAC CTT GTA GAC ATC 
CA <3’ / 5’>TGC ACT TCA GAG AAC CTT G<3’ (43.5°C annealing temperature) and for 
sGCbeta1: biotin 5’>CCC TTC CTT GCT TCT CAG TAG<3’ / 5’>GAC ACC ATG TAC 
GGT TTC GT (49°C annealing temperature). After amplification cells were washed several 
times and incubated with horseradish-peroxidase-complex (1:150, 45 min., room 
temperature). The detection of cells was prepared with DAB solution. 
 
Proteinase-K-buffer   0.5 M Tris-HCl, pH 7.5; 0.5 M EDTA; 0.05 M Sodium Chloride 
 
DAB-solution   0.1 M PB, 1% DAB, 0.75% H2O2 
 
0.1 M PB:   81 mM Di-Sodiumhydrogenphosphate-di-hydrate, 
    19 mM Sodium-di-hydrogenphosphatemonohydrate, pH 7.4 
 
2.22 Statistical analysation 
 
The amount of endostatin binding to vessels was collected on randomly selected endostatin-
labeled tissue sections and is presented as mean ± standard deviation. For each patient 50 
vessels were examined with an Axiophot fluorescence microscope (Zeiss, Oberkochen, 
Germany) using 400-fold magnification (CY2: absorb.: 552 nm and emiss.: 565 nm; CY3 
absorb.: 495 nm and emiss.: 516 nm). 50 vessels per tumour slice and normal tissue slice were 
analysed for each patient. Binding intensity was evaluated by comparison of the fluorescence 
intensity derived from PECAM-1 and endostatin-binding staining. Distinct binding was 
described if the fluorescence intensity derived by endostatin-binding was comparable or 
higher then the fluorescence intensity derived from PECAM-1 staining. In case of 
recognizable but lower fluorescence intensity of binding staining compared to PECAM-
fluorescence staining, a weak binding was described. Statistical analysis was performed using 
the adjusted t test with p-values corrected by the Bonferroni method (p=<0.05). 
All data are presented as mean ± SD. Data analysis are performed using analysis of variance 
with Bonferroni post hoc test and/or Student`s test for unpaired data. Significance was 
considered at a P value < 0.05. 
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3. Results 
 
3.1 Endostatin Binding to Benign and Malignant Bladder, Prostate and Kidney 
Tissues 
 
From western-blot, immunohistochemistry and in situ-hybridisation analysation, we observed 
a distribution and expression of endostatin in both benign and malign bladder, prostate and 
kidney tissue (diploma work), concluding that binding sites for endostatin must be available. 
In order to investigate if a comparable binding pattern could be observed in vivo, we incubated 
cryosections of fixed and sucrose-embedded human bladder, prostate and kidney tissue with 
biotinylated endostatin. The tissue was derived from normal bladder, prostate and kidney 
tissue as well as from bladder, prostate and kidney tumours and benign prostatic hyperplasia 
(BPH). With regard to the bladder tumour tissue, distinct endostatin binding was observed in 
94.2±3.01% of vessels of various diameters ( Tab. 1, Fig. 1A and B), while weak endostatin 
binding was detectable in only 2.0±1.48% of normal bladder tissue vessels (data not shown). 
Significant differences in both the number of vessels showing endostatin binding and the 
binding intensity were observed when comparing benign and malignant prostate tissues 
(p<0.005). While distinct endostatin binding was found in 73.8±19.47% of prostate tumour 
vessels, a weak binding, was seen in 1.7±1.67% of normal prostate vessels (Tab. 1). 
 
 
tissue type endostatin binding vessels [%] 
  
malignant bladder 94.2 +/- 3.01% 
benign bladder 2.0 +/- 1.48% 
malignant prostate 73.8 +/- 19.47% 
benign prostate 1.7 +/- 1.67% 
malignant kidney 11.32 +/- 3.85% 
benign kidney 1.5 +/- 1.73% 
  
 
Table 1: Distribution of endostatin binding in benign and malignant bladder, prostate and kidney tissues.  
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Figure 1: (A, C, F) Immunohistochemical detection of endothelial cells and vessels in bladder, prostate and 
kidney tumour with an anti-human-PECAM-1 antibody. (B) Binding of endostatin to vessels in bladder tumour. 
A distinct binding of endostatin to the PECAM-positive tumour vessels can be seen. (D) Binding of biotinylated 
endostatin to human prostate tumour vessels could be observed. (F) The PECAM-positive kidney tumour vessels 
do not show any endostatin binding. On the other site malignant kidney tumour cells show strong endostatin 
binding. Bar = 10 µm. (G, H, I) Ultrastructural detection of bound endostatin with streptavidin-gold. (G) Bar = 1 
µm, (I) Bar = 70 nm. 
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In contrast to vessels in malignant bladder (Fig. 1A and B) and prostate tissue (Fig. 1C and 
D), only 11.32±3.85% of vessels in malignant kidney tissue (Fig.1E and F) show a weak or no 
detectable endostatin binding (Fig. 1F). The endostatin binding to vessels in benign kidney 
tissue was also weak (data not shown) and restricted to 1.5±1.73% of the vessels (Tab. 1). A 
distinct endostatin binding was observed for BPH in 89.12%±10.72% vessels of various 
diameters (Fig. 2).  
PECAM endostatin
A B
C D
PECAM endostatin
Figure 2: A-D: Endostatin binding to PECAM-positive vessels of prostatic hyperplasia. A and C 
show an immunohistochemical staining with PECAM-1 to marks endothelial cells and vessels. 
B and D show the detection of biotinylated endostatin boundet to these vessels. 
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Figure 2: E: Statistical analysation of endostatin binding to vessels of prostate tissue, prostate 
tumour and BPH. Only few vessels bind endostatin in prostate tissue but significant more 
vessels bind endostatin in prostate tumour. Compared to this significant more vessels bind 
endostatin in BPH.
 
Control experiments, which were performed without biotinylated endostatin, did not show a 
fluorescence signal for any of the tissues (data not shown). Pre-incubation with a 100-fold 
higher concentration of endostatin prevents binding of biotinylated endostatin. Comparable 
results were obtained by using biotinylated restin and heparin mutant endostatin (data not 
shown). On ultrastructural level using extravidin gold to detect the bound biotinylated 
endostatin, the binding could be localised in the perivascular matrix including the endothelial 
basement membrane (Fig. 1G and H) and directly on the endothelial cell membrane as well as 
in endothelial cytoplasm (Fig. 1G and H). Abluminal and luminal membrane invaginations, 
also called caveolea, are preferred binding sites of endostatin (Fig. 1I). 
 
3.2 Expression pattern of collagen XVIII/endostatin in the embryo 
 
An important role for endostatin and restin during tumour development was described in 
literature. By western-blot, immunohistochemistry, in situ-hybridisation and distribution of 
binding sites we also concluded an important role and speculated about their role during 
embryonic vessel development which in terms is comparable with the tumour vasculatisation. 
In order to gain insight into the role of endostatin on embryonic vessel development we first 
analysed its distribution and expression in mouse embryos and EBs. In mouse embryos of 
different age we found positively stained blood islands (Fig. 3A) as well as a strong signal for 
The vascular development is modulated by endostatin and restin                                                               page 46 
collagen XVIII/endostatin in vessels of mesenchymal tissue (Fig. 3B). This was corroborated 
by in situ-hybridisation (Fig. 3C, D) showing high expression of collagen XVIII/endostatin in 
blood islands (Fig. 3C) and mesenchymal cells (Fig. 3D) of mouse embryo, suggesting that 
the site of expression must not coincide with accumulation and site of activity. These results 
indicate that endostatin could play an important role during embryonic angio- and 
vasculogenesis, in case endostatin was cleaved from collagen XVIII, throughout the whole 
embryo during all embryonic stages.  
E 13.5
B
D
E 14.5
A
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C
E 9.5
Figure 3: Immunohistological analysis and in situ hybridisation of endostatin/collagen XVIII in mouse embryos. For  the 
immunohistochemical analysis of mouse embryos (A and B) an anti-endostatin antibody was used. In E10 mouse 
embryos strong staining of blood islands for collagen XVIII/endostatin (A) and of vessels in E13.5 mesenchymal tissue 
(B) was observed. For in situ hybridisation (C and D) a cDNA probe complementary to endostatin mRNA was employed. 
Strong staining of blood islands in E9.5 embryos (C) and expression of collagen XVIII/endostatin in E14.5 mesenchymal 
tissue was observed (D). Bar B = 25 µm. Bar D = 10 µm
 
The immunohistochemical detection does not allow differentiating between collagen XVIII 
and his proteolytic fragments e.g. endostatin. Therefore we addressed by Western Blotting 
whether the activated molecule endostatin is formed in murine embryonic tissue. In fact, we 
obtained bands of different sizes at E 10.5, E 13.5, E 15.5 and E 18.5 (Fig. 4). The 180-kDa 
band represents collagen XVIII, the 38 kDa band represents the NC1-fragment of spliced 
collagen XVIII and the 22 kDa band represents endostatin, the C-terminal fragment of the 
NC1-domain of collagen XVIII. The band for collagen XVIII is very weak whereas the bands 
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for the NC1-fragment and endostatin are clearly stronger; no visible differences in band 
intensities at the different time points of embryonic development were noticed. Thus, the 
major part of immunohistochemically detected protein in embryos is endostatin. 
Lane 1 Lane 2 Lane 3 Lane 4
38 kDa
22 kDa
180 kDa
 
Figure 4: Western-Blot analysis of endostatin/collagen XVIII in mouse embryos of different age. Lane 1: E 10.5, 
lane 2: E 13.5, lane 3: E 15.5 and lane 4: E 18.5. The 180 kDa band was detected at all stages and demonstrates 
collagen VXIII; similarly the 38 kDa protein, the NC1- fragment of collagen XVIII was also seen all embryonic 
stages. The 22 kDa protein represents endostatin, which is the activated proteolytic fragment of collagen XVIII. 
 
We also analysed the immunohistological distribution of collagenXVIII/endostatin in 
embryonic stem cell-derived vessels (Fig. 5) to compare the distribution of the collagen 
XVIII/endostatin in mouse embryo and EBs. For this purpose we stained angioblasts and 
endothelial tubes with a mouse specific PECAM-1 (CD31) antibody (Fig. 5A, C). A double 
immunfluorescence with PECAM-1 and collagen XVIII/endostatin enabled to determine its 
distribution in angioblasts and endothelial tubes. Endostatin is accumulated in endothelial 
tubes of embryoid bodies, in sprouting regions as well as in angioblasts (Fig. 5B, D). These 
results suggest that endostatin plays a similar role in EBs and in the embryo for vasculo- and 
angiogenesis. 
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Figure 5: Immunohistological analysis of embryonic stem cell derived endothelial cells and vessels. In an double 
immunfluorescence vessels and endothelial cells were stained with an anti-PECAM-1 antibody (A and C) as well as an 
anti-endostatin antibody (B and D). Endostatin is distributed in angioblasts and vessels of embryonic stem cell derived 
endothelial cells as well as in sprouting areas of vessel like structures. Bar = 10 µM
 
 
3.3 Embryonic stem cell-derived vessels bind endostatin 
 
From the distribution of the protein endostatin in embryos and EBs we were interested if also 
binding sites for endostatin are existence, which makes these tissue accessible for endostatin. 
In order to analyse the occurrence and the distribution of binding sites for endostatin, which is 
an important determinant for its cell biological action, we biotinylated endostatin. After 
detection of bound biotinylated endostatin, we observed nearly exclusive binding of 
endostatin (Fig. 6A and B), restin (data not shown) as well as of the heparin mutant form of 
endostatin (Fig. 6C and D) to all embryonic stem cell-derived angioblasts, endothelial cells 
and tubes detected by PECAM-1 immunostaining. The binding of biotinylated endostatin was 
abolished by pre-treating EBs with a 100-time overdose of unlabelled endostatin. These 
results were also obtained by using a FITC-conjugated endostatin (data not shown). 
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Figure 6: Binding of biotinylated endostatin and heparin mutant endostatin (R158/R184/R270A) 
to embryonic stem cell derived endothelial cells and vessels. A strong binding of endostatin (B) 
and the heparin mutant endostatin (D) was observed for PECAM-positive vessels (A and C).    
Bar = 10 µM
 
3.4 Role of endostatin during embryonic vessel growth 
 
Since endostatin and its binding sites are distributed in endothelial cells and vessels we 
wondered whether endostatin inhibits embryonic vessel development. This was investigated in 
embryonic stem cell-derived endothelial cells, by examining the number of endothelial tubes 
and the proliferation, apoptosis and migration of endothelial cells in presence of endostatin, 
restin or the heparin mutant.  
Opposite to the described anti-angiogenic effect (O’Reilly et al. 1997) of endostatin we 
observed a dose dependent statistically significant increase in the amount of PECAM-1 
stained endothelial tubes in endostatin treated EBs (50ng/ml: 551.3±95.6; 200ng/ml: 
571.3±183.8 vessels per EB) compared to untreated EBs (343.8±65.3 vessels per EB; Fig. 7 
and 8A, B). Interestingly, also the heparin mutant form of endostatin (Fig. 8B) caused a dose 
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dependent increase in the number of vessels (control: 279±110.7; 50ng/ml: 403.3±139.7; 
200ng/ml: 442±184.2 vessels per EB). To exclude that other cell types within the EBs 
influence the endothelial cells and underlie the endostatin effect, we isolated endothelial cells 
using MACS. We observed also for MACS-sorted endothelial cells a significant increase in 
the amount of endothelial cells after treatment with 50 ng/ml endostatin (control: 
1090.25±89,05 cells; 50ng/ml: 1548.75±254 cells; Fig. 8C). Results for restin were nearly the 
same (data not shown). 
control
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Figure 7: Influence of endostatin on the number of vessels. In vitro differentiated embryonic stem 
(ES) cells were treated with 50 ng/ml and 200 ng/ml endostatin or without (control). After12 days 
PECAM-1 antibody was performed to estimate the number of endothelial cells and vessels. 
The vascular development is modulated by endostatin and restin                                                               page 51 
Endostatin evoked an increase in number of vessels (B and C) when compared to control (A). Bar = 
10 µM.  
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Figure 8: Statistics of the number of vessels in presence of endostatin (A) and the heparin mutant endostatin 
(R158/R184/R270A; (B)). In vitro differentiated ES cells were treated with 50 ng/ml and 200 ng/ml endostatin 
and heparin mutant endostatin as well as without endostatin. After immunostaining with PECAM the number of 
vessels in 6 Embryoid Bodies (EBs) were counted for every condition. MACS-sorted endothelial cells were also 
treated with/without 50 ng/ml endostatin and statistically analysed (C). Mean ± SD, p < 0.05. 
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Next, we investigated how endostatin lead to increased endothelial cell generation by 
determining proliferation. In contrast to previous reports (Dhanabal et al. 1999B, Yamaguchi 
et al. 1999) we detected a significant increase in ES cell-derived endothelial cells after 
endostatin treatment (Fig. 9 and 10) and treatment with restin and heparin mutant endostatin. 
The amount of Ki67-positive nuclei in endothelial tubes was significantly higher after 
treatment with 50 ng/ml and 200 ng/ml endostatin compared to control.  
control
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Figure 9: Proliferation of ES cell-derived endothelial cells under influence of endostatin. In vitro differentiated 
ES cells were treated with 50 ng/ml and 200 ng/ml endostatin and without. Double fluorescence staining with 
The vascular development is modulated by endostatin and restin                                                               page 53 
PECAM- and Ki67 allowed the identification of proliferating endothelial cells and vesselsUnder influence of 
endostatin an increase of Ki67-positive cores in PECAM-positive vessels (B and C) compared to control (A) was 
detected. Bar = 10µM 
In Fig. 9 double staining for the endothelial specific marker PECAM-1 and for the 
proliferation marker Ki67 is depicted. Quantification of the data demonstrates, that a 
significant increase (control: 20.5±3.4; 50ng/ml: 162.2±7.5; 200ng/ml: 188.8±11.8 Ki67-
positive nuclei per 50 vessels) of proliferating endothelial cells (Fig. 10A) is detected after 
exposure to endostatin as well as to the heparin mutant form of endostatin (control: 
23.2±10.3; 50ng/ml: 72.5±12.9; 200ng/ml: 99.2±28.9 Ki67-positive nuclei per 50 vessels; 
Fig. 10B). Results for restin were comparable (data not shown). Having used the Ki67-
antibody we could not completely exclude a G1-arrest (Ki67 is mainly expressed during G1-
phase), which was recently shown for endostatin in endothelial cells (Dhanabal et al. 
1999A,B,C, Hanai et al. 2002). We have therefore analysed the proliferation of endothelial 
cells using BrdU (Fig. 10C, D). Similar to our findings with Ki-67, we also observed with 
BrdU a significant increase of endothelial cell proliferation in presence of endostatin (control: 
57±2.4; 50ng/ml: 167.8±23; 200ng/ml: 180.8±14 BrdU-positive nuclei per 50 vessels) and of 
the heparin mutant endostatin (control: 56±20.01; 50ng/ml: 125±48.8; 200ng/ml: 138±52.1 
BrdU-positive nuclei per 50 vessels). A G1-arrest was further excluded by investigating the 
increase of MACS sorted endothelial cells. Taking together these data (Fig. 8C) supported an 
augmented proliferation.  
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Figure 10: Statistics of the proliferation of endothelial cells under influence of endostatin as well as heparin 
mutant endostatin (R158/R184/R270A). Ki67-positive cores of 50 vessels from 6 EBs per condition were 
counted (A and B). In the same way BrdU-positive cores of 50 PECAM-positive vessels from 6 EBs per 
condition were counted (C and D). Mean ± SD, p < 0.05. 
 
Due to the fact that the very high proliferation rate is not in accord with the increase of vessels 
we wondered whether endostatin influences the cell cycle of embryonic endothelial cells in 
the direction of apoptosis. For this purpose we used as a model the embryonic stem cell-
derived endothelial cells and performed via double immunohistochemical staining (Fig. 11A, 
B) with the endothelial cell marker PECAM-1 and the apoptosis markers activated caspase-3 
or Poly(ADP-Ribose)-Polymerase, PARP, (p85-fragment). As described before (Dhanabal et 
al. 1999A, Dixelius et al. 2000) we could detect an increased endothelial apoptosis under the 
influence of endostatin (Fig. 11B, C) compared with control (Fig. 11A, C); in fact apoptotic 
cell cores (Fig. 11A, B arrows) are visible in PECAM-positive vessels. The statistical data 
corroborate a significant increase of the apoptosis rate in endothelial cells for endostatin 
(control: 17.5±8.1; 50ng/ml: 100.8±23.8; 200ng/ml: 114±30.2 PARP-positive cores per 50 
vessels; Fig. 11C) as well as for the heparin mutant form of endostatin (control: 16±5.7; 
50ng/ml: 70.7±23.3; 200ng/ml: 85.3±25.5 PARP-positive cores per 50 vessels; Fig. 11 D). 
Results for restin were comparable (data not shown). 
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Figure 11: Apoptosis of ES cell-derived endothelial cells under influence of endostatin. After double immunfluorescence with anti-
PECAM-1 antibody and anti-activated caspase-3 antibody or anti-PARP (p85 fragment) apoptotic cores (A and B, arrows) and vessels 
could be seen. For the statistical analysis of endothelial apoptosis (C and D) apoptotic core of 50 vessels from 6 EBs per condition were 
counted. Apoptosis were measured under influence of endostatin (C) as well as under influence of heparin mutant endostatin (D). Mean 
± SD, p < 0.05. Bar = 10 µM
The migration of endothelial cells is an important cell biological aspect for vasculo- and 
angiogenesis. Therefore we analysed next the endostatin effect on migration of ES cell-
derived endothelial cells (Fig. 12) in a Boyden-chamber (Dhanabal et al. 1999B and C, 
Yamaguchi et al. 1999). Under the influence of endostatin (50 ng/ml: 662±236 cells; 200 
ng/ml: 702±14.7 cells) and the heparin mutant endostatin (50 ng/ml: 599±7.2 cells; 200 
ng/ml: 603±21.2 cells) we noticed a significantly enhanced endothelial cell migration as 
compared to control (437±88 cells; Fig. 12 A and B). In order to exclude that this effect was 
due to increased proliferation instead of migration we chose a migration time of 8 hours. This 
excluded proliferation as potential mechanism since the minimum cell division time averaged 
10 to 38 hours (Smith 1982, Edmunds and Adams 1981, Gallwitz 1981). 
No difference between control and the treatment with control peptide M2BPI H2 could be 
observed for all analysed angiogenic aspects (data not shown).  
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Figure 12: Statistical data of endothelial migration under influence of endostatin as well as heparin mutant 
endostatin. After preparing a migration assay in a modified Boyden chamber under influence of 50 ng/ml and 200 
ng/ml endostatin as well as without endostatin, the cells were counted which migrated from the top of the 
membrane to the bottom within 8 h. The migration assay was prepared for endostatin (A) as well as heparin 
mutant endostatin (B). 
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3.5 Endostatin influences the morphology of endothelial cells and tube 
formation 
 
We hypothesised that endostatin influences the morphology of embryonic stem cell-derived 
endothelial cells as described for other models before (Bloch et al. 2000, Dixelius et al. 2000, 
Mundhenke et al. 2001, Read et al. 2001). To analyse this we used high-resolution 
deconvolution microscopy with 3D-reconstruction (Fig. 13). After deconvolution microscopy 
we observed for vessels of EBs, flat PECAM-positive bands and after three-dimensional 
reconstruction (Fig. 13A) we could see that these vessels form flat bowls or grooves. 
However, for endothelial tubes of EBs we observed after three-dimensional reconstruction a 
modulatory effect of endostatin on ES-cell derived endothelial cells (Fig. 13B) in form of 
contraction. To investigate this in detail we analysed the effect of endostatin on the 
morphology of endothelial cells and endothelial tubes with vital microscopy.  
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Figure 13: Morphological analysis by using high resolution deconvolution microscopy. 
The influence of endostatin on the morphology of in vitro differentiated ES cell- derived 
endothelial cells and vessels were analysed by high resolution deconvolution microscopy 
with 3D-reconstruction under influence of endostatin (B) as well as without endostatin 
(A). Without endostatin PECAM-positive vessels resemble grooves or bowls (A) 
whereas after treatment of endostatin vessels appear to be angiogenic-modulated in form 
of contraction (B). Bar = 1.4 µm
 
To visualize endothelial tubes within EBs we employed transgenic ES cell lines where the live 
reporter EGFP is driven by the PECAM-1 promoter (Kazemi et al. 2002). During observation 
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(Fig. 14) we detected continuous rebuilding events (Fig. 14 A and B) but after addition of 
endostatin (Fig. 14 C-F) sudden endothelial contractions occurred, leading to retraction of the 
endothelial tubes and cells. Thus, endostatin induces immediate changes in the morphology of 
endothelial tubes.  
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Figure 14: Vital microscopic analysis of vessel morphology under influence of endostatin in a 
period of  6 h. Under in vitro conditions ES cell-derived endothelial cells form vessel like 
structures (arrows, A and B). In presence of endostatin (C-F) contraction as well as a retraction 
of endothelial cells and vessel like structures were observed (arrows). The time period between 
pictures is 2-3 h. Bar = 20 µm
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3.6 Role of endostatin, restin and the heparin mutant form of endostatin during 
wound healing 
 
The vital microscopic observation is an example for physiological vessel development what 
also the regenerative neovascularisation of wound healing is a model system for. From 
endostatin expression in hyperproliferative epithelium and in endothelial cells of microvessels 
during wound healing (Bloch et al. 2000) we were able to evidence an endostatin-mediated 
effect. Therfore we analysed vessel quantity, proliferation and apoptosis during regenerative 
neovascularisation of physiological wound healing. We further investigated the mechanism 
the anti-angiogenic protein, restin and the heparin binding mutant form of endostatin. After 
treatment of wounded mice with endostatin we found an increase in vessel quantity (520±20 
vessels/mm²) compared to control (315±114 vessels/mm²) (Fig. 15A and B, Fig. 16A). This 
was also observed after treatment with restin (496±41 vessels/mm²) and R158/R184/R270A 
(525±41 vessels/mm²) (Fig. 15A-D, Fig. 16A). Therefore we asked for proliferation rate and 
observed an increase in endothelial proliferation in wound areas after treatment with 
endostatin (2.8±0.4 Ki67-positive vessels/mm²), restin (2.5±1 Ki67-positive vessels/mm²) 
(Fig. 15F, Fig. 16B) as well as R158/R184/R270A (1.4±1.1 Ki67-positive vessels/mm²) 
compared to control (0.5±0.8 Ki67-positive vessels/mm²) (Fig. 15E, Fig. 16B). From the fact 
that the increase in endothelial proliferation was not in accord with the increase in vessel 
amount, we conclude that endostatin influence cell cycle during wound healing in direction of 
apoptosis. What we observed in endothelial cells of wounded areas was increased apoptosis 
after treatment with endostatin (2.6±0.8 apoptotic vessels/mm²), restin (2.2±0.8 apoptotic 
vessels/mm²) (Fig. 15H, Fig. 16C) and the heparin mutant form of endostatin 
(R158/R184/R270A) (1.6±1.1 apoptotic vessels/mm²) compared to control (1±0.9 apoptotic 
vessels/mm²) (Fig. 15G, Fig. 16C).  
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Figure 15: Influence of endostatin, restin and the heparin mutant form of endostatin on 
vessel quantity, endothelial proliferation and apoptosis during wound healing. Wound 
healing under influence of endostatin (B), restin (C) and the heparin mutant form of 
endostatin (D) lead to an increase in vessel quantity in 5d old wounds compared to control 
(A). This proteins also lead to an increased endothelial proliferation here shown for restin 
(F) compared to control (E) as well as to an increased apoptosis, as shown for restin (H) 
compared to control (G).
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Figure 16: Statistical analysation of the amounts of vessel, the endothelial proliferation and apoptosis. (A) 
Vessels under influence of endostatin, restin and the heparin mutant form of endostatin show an increased 
amount of endothelial cells in wounded areas. (B) Also the proliferation and (C) the apoptosis was increase under 
influence of these three proteins. 
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3.7 Do restin and heparin mutant endostatin influence the morphology of 
endothelial cells and vessels? 
 
Endostatin influences the morphology of embryonic stem cell derived endothelial tubes (as 
described above), of vessels during wound healing (Bloch et al. 2000, Mundhenke et al. 2001) 
as well as of vessels in tumour tissue (Mundhenke et al. 2001, Read et al. 2001). But till now 
it was not analysed whether restin and the heparin mutant form of endostatin have also an 
effect on vessel morphology. In semi-thin sections of wound areas we observed a comparable 
morphological change for endothelial cells and vessels after treatment with restin and 
R158/R184/R270A (Fig. 17C and D) as observed for endostatin (Fig. 17B + Bloch et al. 
2000) compared to control (Fig. 17A). Vessels were narrowed or closed and irregular in 
shape, thereby restricting the integration in the circulation system. Thus a significant reduction 
in number of functional vessels was observed in wounds of endostatin treated mice. On the 
contrary vessels of buffer injected animals were round, open and filled with blood cells. Data 
were further confirmed by ultrastructural analyse (Fig. 17E-H). Also in this case, we also 
observed narrowed or closed vessels because of either a contraction of vessels in wound areas 
or a lack of lumen building after treatment with endostatin, restin and R158/R184/R270A 
(Fig. 17F-H) compared to control (Fig. 17E).  
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Figure 17: Vessel morphology during wound healing under influence of endostatin, restin 
and the heparin mutant form of endostatin, analysed on semi-thin and ultra structural level. 
On semi-thin level (A-D) we observed under influence of endostatin (B), restin (C) and the 
heparin mutant form of endostatin (D) a modulated vessel morphology in form of a 
contraction. Vessels were narrowed or closed compared to control (A). Also on ultra 
structural level we observed under influence of endostatin (F), restin (G) and the heparin 
mutant form of endostatin (H) narrowed or closed vessels compared to control (E).
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To answer the question if endostatin-mediated morphological changes of vessels are a 
consequence of a lacked lumen building or of a contraction, we analysed this morphological 
changes under influence of endostatin, restin and R158/R184/R270A in form of a dynamic 
process, by performing vital microscopic examination. For this purpose we transfected 
embryonic stem cells with the vital reporter gene GFP under an endothelial-specific promotor 
(Kazemi et al. 2002) which facilitates us to analyse the influence of this three factors on the 
development of embryonic stem cell derived endothelial tubes. During the vital microscopic 
analysation of GFP-positive tubes (Fig. 18), we observed continuous rebuilding events (Fig. 
18 A, D and G). But from the supply of endostatin we observed, with a temporal delay -as 
described before- fast contraction and retraction of endothelial cells and tubes (Fig. 18B and 
C), which lead to a loss of the integrity. This finding was also seen for restin (Fig. 18D-F) and 
the heparin mutant form of endostatin (Fig. 18G-I). All three factors modulate vessel 
morphology in wounded areas as well as during vital microscopic examinations in a 
comparable way. This described modulation of vascular morphology was limited on vessels 
and endothelial tubes of a defined differentiation degree. The defined differentiation degree 
means endothelial tubes and vessels, which have started to mature and started to build up a 
lumen. Comparable morphological changes of endothelial tubes were also observed under 
influence of the MAP-kinase inhibitor PD98059 (data not shown).  
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Figure 18: Vital microscopic analysation of GFP-positive endothelial tubes under influence of 
endostatin, restin and the heparin mutant form of endostatin. Endothelial tubes of in vitro 
differentiated embryonic stem cells were visualised by the vital reporter gene GFP under an 
endothelial specific promotor. By vital observation of endothelial tubes under influence of 
endostatin (A-C), restin (D-F) and the heparin mutant form of endostatin (G-I) over a period of 
6h we observed a modulation of endothelial morphology in form of a contraction and retraction. 
The sequence of pictures makes the pull together, the retraction visible. 
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restin restin restin
RA RA RA
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endostatin endostatin endostatin
 
 
3.8 Do endostatin, restin and heparin mutant endostatin influence 
signaltransduction?  
 
Morphological changes of vessels mainly underlie the influence of angiogenic factors like 
VEGF. For morphological changes of vessels VEGF is an important factor. Therefore we 
checked if endostatin, restin and R158/R184/R270A influence the VEGF signaling pathway as 
well as components of this pathway like VEGF, Flk-1, eNOS, sGC, cGMP and ERK1/2-
kinase as well as AKT-kinase. For two of this components (sGC and activated ERK1/2-
The vascular development is modulated by endostatin and restin                                                               page 67 
kinase) we observed changes of expression and phosphorylation respectively after treatment 
with endostatin, restin as well as R158/R184/R270A (Fig. 19). Treatment of mice during 
wound healing leads to a dephosphorylation of the activated ERK1/2-kinase (Fig. 19A and B) 
as well as to a down-regulation of the soluble guanlyate cyclase (sGC) in vessels (Fig. 19C 
and D). Whereas no changes for the activated AKT-kinase after treatment with endostatin, 
restin and R158/R184/R270A (Fig. 19E and F) were observed. Also for VEGF, Flk-1 and 
eNOS we did not observed any changes in vessels after treatment (data not shown). Under 
influence of endostatin, restin and R158/R184/R270A there is a significant reduction of 
vessels which are positive for phosphorylated ERK1/2-kinase (9.4 ± 3.2 / 9.56 ± 5.3 / 6.3 ± 
2.1 ERK-positive vessels/mm²) as well as for sGC (9.2 ± 3.2 / 14.96 ± 7.1 / 10.36 ± 5.6 sGC-
positive vessels/mm²) (Fig. 20A and B) in wounded areas, whereas the amount of positive 
vessels for the phosphorylated AKT-kinase (84.7 ± 29 / 102.52 ± 15.1 / 98.8 ± 18.1 AKT-
positive vessels/mm²) did not changed (Fig. 20E and F). 
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Figure 19: Signal transduction in endothelial cells of wounded areas under influence of 
endostatin, restin and the heparin mutant form of endostatin. Under influence of this three 
proteins we observed a dephosphorylation of ERK1/2-kinase in endothelial cells and vessels here 
shown for restin (B) compared to control (A). Also we observed a down-regulation of sGC in 
endothelial cells and vessels of wounded areas under influence of this three protein as shown for 
restin (D) compared to control (C). Whereas activated AKT-kinase was not influences in 
endothelial cells and vessels under influence of endostatin, restin (F) and the heparin mutant form 
of endostatin compared to control (E). 
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Figure 20: Statistical analysation of the signalling molecules activated ERK1/2-kinase, sGC and 
activated AKT-kinase in vessels under influence of endostatin, restin and the heparin mutant form of 
endostatin in wounded areas. Vessels positive for the activated ERK1/2-kinase (A) were reduced 
under influence of endostatin, restin and the heparin mutant form of endostatin. SGC-positive vessels 
(B) were also reduced under influence of these three proteins, whereas the activated AKT-kinase (C) 
was not reduced in endothelial cells. Mean ± SD p<0.05 
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In order to control if the described influence on components of the VEGF signaling pathway is 
also visible for embryonic stem cell derived endothelial tubes in EBs, a model which allowed 
us to analyses directly the influence of the altered signaling pathway on morphology of 
endothelial tubes, we treated embryoid bodies (EBs) with endostatin, restin, and 
R158/R184/R270A for 12 days. After immunohistochemistry we observed a 
dephosphorylation of the activated ERK1/2-kinase in PECAM-positive tubes (Fig. 21C and 
D) whereas a strong expression was observed for control (Fig. 21A and B). We observed also 
a down-regulation of sGC in PECAM-positive endothelial tubes of EBs (Fig. 21G and H) 
compared to control (Fig. 21E and F).  
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Figure 21: Signal transduction in endothelial tubes of in vitro differentiated stem cells. Under 
influence of endostatin, restin and the heparin mutant form of endostatin we observed a 
dephosphorylation of ERK1/2-kinase in PECAM-positive endothelial tubes as shown for restin (C and 
D) compared to control (A and B). Also we observed a down-regulation of sGC under influence of 
this three proteins in endothelial tube, as shown for restin (G and H) compared to control (E and F).   
Questioning for the period of time in which down-regulation of this signaling molecules takes 
place we observed no reduction in endothelial tubes positive for the activated ERK1/2-kinase 
within 1 hour of treatment (Fig. 22B) but a beginning of down-regulation after 3 hours (Fig. 
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22C). After 6 hours we observed a nearly complete dephosphorylation of ERK1/2-kinase in 
vessels of EBs (Fig. 22D). For the soluble guanylate cyclase (sGC) any down-regulation was 
observed within a period of 3 hours (Fig. 22C) but a nearly complete down-regulation after 6 
hours (Fig. 22D).  
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Figure 22: Statistical analysis of the number of endothelial tubes displaying ERK1/2-kinase 
dephosphorylation and sGC down-regulation under the influence of endostatin over a period of 6 
hours (A-D). This effect was analyzed after 1 hour (B), 3 hours (C), 6 hours (D) as well as without 
endostatin incubation (0 hour, A). At each time point the number of endothelial tubes with strong, 
weak or no signal were counted. Mean ± SD p<0.05. 
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3.9 Is the effect of endostatin NO/cGMP dependent? 
 
Endostatin mediates the dephosphorylation of the activated ERK1/2-kinase and down-
regulation of sGC, both molecules of the VEGF/Flk-1/eNOS/sGC/cGMP/ERK signaling 
pathway (Parenti et al. 1998, Kroll and Waltenberger 1997). Further it was shown that 
endostatin inhibits the activity of eNOS (Urbich et al. 2002), which lays upstream of sGC and 
activated ERK1/2-kinase. As a consequence of less eNOS activity there is a down-regulation 
of cGMP (Verma et al. 2002). To answer the question if endostatin’s effects on sGC and 
activated ERK1/2-kinase could be the consequence of its influence on upstream signaling 
molecules, we treated EBs with 8bromo-cGMP a cell permeable derivat of cGMP. From 
immunohistochemical analysis we observed that 8bromo-cGMP, which did not influence the 
activated ERK1/2-kinase by itself (Fig. 23A and B), prevents endostatin-meditated 
dephosphorylation of the activated ERK1/2-kinase (Fig. 23C and D) after preincubation with 
endostatin in a period of 30 min. Simultaneously by vital microscopy we observed a prevented 
endostatin-mediated retraction of endothelial tubes after treatment with 8bromo-cGMP when 
preincubation with endostatin was in a period of 30 min. (Fig. 24A-C). Because of the fact 
that endostatin-mediated retraction of endothelial tubes as well as the dephosphorylation of 
the activated ERK1/2-kinase takes place with a temporal delay we wondered if an initiated 
dephosphorylation, as well as an introduced retraction of vessels is also preventable by 
8bromo-cGMP. To answer this question, we treated EBs for 1 hours and more with endostatin 
before we treated them with 8bromo-cGMP. After immunohistochemistry we observed the 
described endostatin-mediated dephosphorylation of the activated ERK1/2-kinase (Fig. 23E 
and F). An initiated endostatin-mediated dephosphorylation of ERK1/2-kinase could not be 
blocked by 8bromo-cGMP and was not reversible. By vital microscopy we observed that 
preincubation with endostatin for 1 hour and more before treatment with 8bromo-cGMP leads 
to the described endostatin-mediated retraction of endothelial cells (Fig. 24D-F). An initiated 
endostatin-mediated retraction of endothelial tubes was not preventable by 8bromo-cGMP. 
Treatment with 8bromo-cGMP could not influence the endostatin-mediated down-regulation 
of the sGC (data not shown).  
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Figure 24: Vital microscopic observation of endostatin-mediated modulation of endothelial tube 
morphology under influence of 8bromo-cGMP. For vital observation stem cell derived endothelial 
tubes where pre-incubated for 30 min. with endostatin and then treated with 8bromocGMP (A-C). 
8bromo-cGMP was able to block endostatin-mediated retraction of endothelial tubes (A-C). By pre-
incubation of 1h and more with endostatin, 8bromo-cGMP was not able to block endostatin-mediated 
retraction of endothelial tubes (D-F).  
In order to answer the question if the endostatin-induced dephosphorylation of ERK1/2-kinase 
is directly mediated by cGMP reduction, we analysed if the sGC-inhibitor ODQ was also able 
to induce these endostatin-mediated effects. Therefore we treated EBs with ODQ. After 
immunohistochemistry we neither observed dephosphorylation of ERK1/2-kinase (Fig. 26A 
and B) nor down-regulation of sGC in PECAM-positive vessels (Fig. 26C and D). 
Additionally we asked if the endostatin-mediated dephosphorylation of ERK1/2-kinase as 
well as the down-regulation of sGC are preventable by an increase of NO. To answer this 
question, we treated EBs simultaneously with the NO-donor NONOate and endostatin. After 
immunohistochemical detection we observed activated ERK1/2-kinase in PECAM-positive 
endothelial tubes. An increasing level of NO was able to block the endostatin-mediated 
dephosphorylation of ERK1/2-kinase (Fig. 25C and D) whereas NONOate alone did not 
influence ERK1/2-kinase phosphorylation (Fig. 25A and B). 
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Figure 25: Influence of the NO-donor NONOate on the endostatin-mediated 
dephosphorylation of the activated ERK1/2-kinase in endothelial tubes of in vitro 
differentiated stem cells. The NO-donor by itself did not influence the activated ERK1/2-
kinase (B) in PECAM-positive endothelial tubes (C). 
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Figure 26: Analysation of ODQ effect on the activated ERK1/2-kinase and sGC in 
endothelial tubes of in vitro differentiated stem cells. The sGC-inhibitor ODQ did not 
influence the phosphorylation of the activated ERK1/2-kinase (B) in PECAM-positive 
endothelial tubes (A). Also under influence of ODQ we did not observed a down-regulation 
of sGC (D) in PECAM-positive endothelial tubes (C). 
 
3.10 Are further pathways concerned? 
 
As described by Urbich et al. endostatin increase significantly the activity of the Ser/Thr 
protein phosphatase PP2A (Urbich et al. 2002). To answer the question if PP2A also is 
responsible for dephosphorylation of ERK1/2-kinase and down-regulation of sGC we treated 
EBs simultaneous with the PP2A-inhibitor ocadaic acid and endostatin. After 
immunohistochemistry neither an endostatin-mediated dephosphorylation of ERK1/2-kinase 
(Fig. 27C and D) nor a down-regulation of the sGC (Fig. 27G and H) was observed in 
endothelial tubes whereas PP2A alone did not influence phosphorylated ERK1/2-kinase (Fig. 
27A and B) or sGC (Fig. 27E and F). By inhibition of PP2A we were able to block endostatin-
mediated dephosphorylation of ERK1/2-kinase and down-regulation of sGC. Consequently 
endostatin-mediated effects are induced by PP2A.  
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Figure 27: Influence of PP2A-inhibitor, ocadaic acid on the endostatin-mediated dephosphorylation of 
ERK1/2-kinase and down-regulation of sGC in endothelial tubes of in vitro differentiated embryonic stem 
cells. PP2A-inhibition by itself did not influenced ERK1/2-kinase phosphorylation (B) in PECAM-positive 
endothelial tubes (A) but after pre-incubation with endostatin, PP2A-inhibition blocked the endostatin-
mediated dephosphorylation of the ERK1/2-kinase (D) in PECAM-positive endothelial tubes (C). PP2A-
inhibition by itself also did not influence sGC (F) in PECAM-positive endothelial tubes (E) but after pre-
incubation with endostatin PP2A-inhibitor ocadaic acid was able to block endostatin-mediated down-
regulation of sGC (H) in endothelial tubes (G). 
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3.11 Is the reduction of sGC a consequence of transcriptional modification? 
 
Regarding endostatins’ influence it was clear, that the observed down-regulation of the 
activated ERK1/2-kinase in endothelial cells and vessel like structures was the consequence of 
a dephosphorylation because of an unchanged level of the common ERK1/2-kinase. But for 
the down-regulation of sGC it was unclear if the down-regulation takes place on the 
transcriptional level or on posttranscriptional level. In order to get an inside we performed RT 
in situ PCR and examined if the level of sGC mRNA was changed under influence of 
endostatin. But the level of sGCalpha1 mRNA as well as sGCbeta1 mRNA was unchanged in 
MACS-sorted endothelial cells after endostatin treatment, compared to control (data not 
shown). 
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4. Discussion 
 
4. 1 The heparin-binding site is not necessary for endostatin action 
 
In literature contrasting views exist on the importance of the endostatin heparin-binding site. 
Whereas Hohenester et al. 1998, Sasaki et al. 1998/1999 and Karumanchi et al. 2001 conclude 
that the heparin binding site of endostatin is necessary for its anti-angiogenic activity, Chang 
et al. 1999 and Yamaguchi et al. 1999 suggest that the anti-angiogenic effect of endostatin is 
independent from its heparin binding site. In this work we have found that the heparin mutant 
form of endostatin (R158/R184/R270A) has nearly the same effects as normal recombinant 
endostatin. This indicates that the heparin-binding site of endostatin is not necessary for its 
biological action. However the effects of the heparin mutant form shows a weakening 
compared to endostatin. A reason therefore could be a changed or reduced binding to the 
binding sites. Also a changed folding of the protein after mutagenesis could be a reason for. 
 
4.2 Reason for contrasting results regarding the endostatin-mediated effects 
 
It is noteworthy, though, that the endostatin concentrations used were often very high and 
could potentially cause the contrasting results. In fact the groups of Feraud et al. 2001 and 
Eriksson et al. 2003 report an inhibition of the density and sprouting of endothelial cells in 
EBs under the influence of endostatin. These contrasting results were obtained employing 60-
300 fold higher endostatin concentrations as the present study and other differentiation 
protocols.  
 
4.3 Binding of endostatin, restin and heparin mutant endostatin to tumour and 
embryonic vessels 
 
Researchers have discovered that endostatin is a potent inhibitor of angiogenesis and tumour 
cell growth, while having no effect on a resting vascular system (O’Reilly et al. 1997, Bloch et 
al. 2000). In order to understand which vessels might be influenced by endostatin, we 
analysed the binding behaviour of endostatin with benign and malignant tissue. Altogether, 
our results show that endostatin exhibits different vascular binding properties for benign and 
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malignant tissue. Bladder and prostate tumours expressed binding sites for endostatin on the 
vessels. The significantly lower degree of endostatin binding to kidney tumour vessels 
indicates that the binding characteristics of the vessels of different types of tumours are not 
uniform.  
The assumption that there are differences among various endothelial cell systems has recently 
been discussed. It has been postulated that endothelial cells from benign and malignant tissues 
are dissimilar on the molecular level and it has been demonstrated that endothelium derived 
from tumours is qualitatively different from that obtained from benign tissue (StCroix et al. 
2000). These differences between endothelial cells in benign and malignant tissues could 
explain the diverse endostatin binding patterns seen in the vessels of the tissues investigated. 
Eberhard et al. give evidence that vessels in tumour tissues can be selectively targeted without 
affecting the quiescent organ vascularity (Eberhard et al. 2000). This fact is explained by the 
different molecular phenotypes of immature angiogenic blood vessels, which are distinct from 
resting blood vessels (StCroix et al. 2000). Subsequently, many animal studies have shown 
the feasibility of selectively targeting activated proliferating vascularity, without affecting 
normal organ vasculature (Bloch et al. 2000, Friedlander et al. 1995, Mauceri et al. 1998, 
Ferrara et al. 1998). Therefore the tumour vascular bed is indicated as a possible therapeutic 
target for cancer treatment (Tosetti et al. 2002). 
A different form of functional immaturity could also explain the variations in endostatin’s 
binding behaviour, seen when comparing bladder tumour vessels with those in kidney 
tumours. There may be discrepancies in the angiogenic potency of various kinds of 
endothelial cells, as has been described by other research groups, who found both anatomical 
and angiogenically-active vessels (Kumar et al. 1999, Ding et al. 2001).  
Thus, endostatin binding is seen in most vascular endothelial cells in malignant bladder and 
prostate tissues, but it is significantly lower in endothelial cells from malignant kidney 
tumours. It could be speculated that endostatin causes a stable phenotype in superficial 
bladder tumour vessels, which leads to a low incidence of hematogenous metastasis in these 
malignant bladder lesions (Messing and Catalona 1998). The same reasoning can also be used 
to explain the similar low incidence of hematogenous metastasis in the vessels of cancerous 
prostate tissue (Oefelin et al. 1999, Moreno et al. 1992, Ablin 1993). Furthermore, the weak or 
absent binding of endostatin to vascular endothelial cells in malignant kidney tissues could 
explain the relatively high incidence of hematogenous metastasis observed in these tumours 
(Messing and Catalona 1998). As mentioned above, possible variations in endothelial 
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phenotypes may explain this characteristic and may subsequently lead to an aggressive growth 
pattern for malignant kidney tumours as compared to that of superficial bladder tumours. 
Because of a high amount of endostatin binding sites, malignant bladder and prostate tissue 
could be a target for a therapy based on endostatin treatment. Also the BPH, which shows 
high amounts of binding sites for endostatin compared to normal prostate tissue, makes this 
tissue accessible for an endostatin treatment. A strong binding of endostatin to vessels of 
bladder and prostate carcinoma as well as BPH give hint for a therapeutic benefit by 
angiogenesis inhibition. 
A lot of binding sites for endostatin could also be observed in vessel-like structures of 
differentiated embryonic stem cell cultures. This strong binding to such structures suggests an 
angio-modulatory role of endostatin and restin during embryonic vessel development. The 
above mentioned differences in endostatin binding to different kinds of tumours but a strong 
binding to embryonic vessels could be possibly explained by the existence of different binding 
sites for endostatin i.e. glypican and tropomyosin with varying affinity for the ligand 
(Karumanchi et al. 2001, MacDonald et al. 2001). This result is supported by the fact that 
endostatin binds to embryonic stem cell-derived endothelial cells and vessels with high 
affinity but not to endothelial cell lines like PAEC and HUVEC (data not shown). We 
therefore assume, that differences in endothelial cell biology like maturation, differentiation 
and origin can influence the distribution of binding sites and consequently the ability to bind 
endostatin, which entails differences in its biological effects.  
Because of these different binding sites signalling through more than one pathway is likely. In 
fact, a large variety of different signaling pathways, regulated by endostatin, have been 
described so far (Dixelius et al. 2000, Jiang et al. 2001, Shichiri and Hirata 2001). 
Furthermore the interaction with VEGF-R2 and α5ß1 or αvß3 integrin as targets for 
endostatin leading to alteration of angiogenic effects have also been reported (Furumatsu et al. 
2002; Kim et al. 2002). 
 
4.4 Cell biological aspects during embryonic vessel growth under influence of 
endostatin 
 
We here show that endostatin is expressed in embryonic vessels and blood islands. Moreover, 
the demonstration of endostatin binding sites suggests an angiogenic regulatory role for 
endostatin during embryonic development. The proposed function of endostatin is rather 
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angio-modulatory than exclusively anti-angiogenic because of both, pro- and anti-angiogenic 
effects during embryonic vascular development. In fact the anti-angiogenic effects in form of 
increased apoptosis and altered morphogenesis balance the pro-angiogenic effects in form of 
endothelial cell proliferation and migration. 
The modulation of angiogenesis is one of the most attractive approaches to regulate tissue 
growth in pathological and physiological processes such as neoplasia, ischemic and 
inflammatory diseases and wound healing. It also plays an important role for the embryonic 
development. Angiogenesis is a complex process, comprising activation, proliferation and 
migration of endothelial cells, alteration of the extracellular matrix, formation of endothelial 
tubes and networks, and their linkage to pre-existing vascular networks. This complicated 
mechanism is modulated by several angiogenic and anti-angiogenic molecules (Hanahan and 
Folkman 1996, Risau 1997, Carmeliet and Jain 2000).  
The investigation of angiogenesis during development could help to understand better general 
and tissue specific mechanisms of regulation by angiogenic and anti-angiogenic factors. One 
of these factors is endostatin, which constitutes one of the most promising anti-angiogenic 
molecules currently tested in clinical trials (Ryan et al. 2002), characterized by a variety of 
effects and in particular by its heterogenous anti-angiogenic potential (Ramchandran et al. 
2002). Our results on the role of endostatin during embryonic development demonstrate a 
variety of different effects on vasculo- and angiogenesis. These novel findings allow to 
compare the role of endostatin during embryonic development with earlier results for wound 
healing (Berger et al. 2000, Bloch et al. 2000, Mundhenke et al. 2001) and tumour growth 
(O`Reilly et al. 1997) in order to better understand the complex role of this molecule in the 
regulation of physiological and pathological angiogenesis. 
Experiments for wound healing show that endostatin does not cause inhibition of regenerative 
vessel development (Berger et al. 2000, Bloch et al. 2000, Mundhenke et al. 2001), but plays a 
role for the morphogenesis of new formed vessels and the damage of endothelial cells (Bloch 
et al. 2000, Mundhenke et al. 2001). Our observations in EBs suggest that endostatin plays a 
similar role during embryonic vessel growth. We demonstrate that endostatin leads to 
contraction or lack of expansion of endothelial cell forming vessels and retraction of 
endothelial sprouting as well as apoptosis of endothelial cells. The morphogenic findings can 
explain the mechanism whereby the vessel diameter is reduced in tumours after endostatin 
treatment. In accordance to previous reports (Dhanabal et al. 1999A, Dixelius et al. 2000) we 
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also provide evidence that endostatin works as negative regulator of embryonic angio- and 
vasculogenesis by stimulating the apoptosis of endothelial precursors.  
The complex mode of action of this molecule is further underlined by the observation that 
besides the anti-angiogenic effects of endostatin also pro-angiogenic actions such as increased 
proliferation and migration of ES cell-derived endothelial cells are noted. 
Similar to endothelial cell migration Boye et al. 2001 could show that the migration of 
hemangioma-derived endothelial cells isolated from infants was stimulated after endostatin 
treatment. These findings imply that endothelial cells with a basal high angiogenic activity 
display different migratory characteristics to endothelial cell lines like HUVEC without basal 
angiogenic activity. In these cell types migration is inhibited after endostatin treatment 
(Dhanabal et al. 1999 B and C, Yamaguchi et al. 1999). We therefore propose that endothelial 
cell migration by endostatin depends on the origin and /or differentiation stage of cells. 
The endostatin-mediated increase of the vessel number during embryonic development could 
be explained by the increase of endothelial proliferation in presence of endostatin in EBs. 
However, the amount of vessels does not increase in proportion to the high proliferation rate, 
which is explained by the counter-acting increased apoptotic endothelial cell death.  
For proliferation several recent studies using VEGF or FGF stimulated micro- and 
macrovascular endothelial cell from primarily angiogenic quiescent vessels, which showed in 
opposite anti-proliferative effect of endostatin, supporting our assumption of endothelial cell 
type specific regulation. 
 
4.5 Endothelial cell biological aspects during wound healing under influence of 
endostatin 
 
The tumour-inhibitory protein endostatin did not concern neovascularisation during wound 
healing as demonstrated during this study as well as by others (Berger et al. 2000, Bloch et al. 
2000, Mundhenke et al. 2001). The conclusion that neovascularisation of tumour tissue and 
during wound healing are different processes was confirmed by the findings that tumour 
endothelium, in general, is different from the surrounding normal tissue (St. Croix et al. 
2000).  
During the present story it has been observed in the present of the anti-angiogenic proteins 
endostatin, restin and the heparin binding mutant form of endostatin an influenced but not an 
The vascular development is modulated by endostatin and restin                                                               page 84 
inhibited neovascularisation during wound healing. These factors increase vessel quantity and 
this could be explained by a shift of the balance between proliferation and apoptosis.  
The fact that endostatin, restin and the heparin mutant form of endostatin lead to an increased 
vessel quantity during wound healing was confirmed by the experiments with embryonic stem 
cell derived endothelial cells and vessels and it agrees with the observation of an increased 
proliferation after treatment with these factors during wound healing as well as demonstrated 
for embryonic stem cell derived endothelial tubes. Comparable with these results Lai et al. 
could show that patients with high level of plasma endostatin show an increased angiogenesis 
in tumours (Lai et al. 2002). The demonstrated increase in endothelial apoptosis during wound 
healing after treatment with endostatin, restin and the heparin mutant form of endostatin 
agrees with our previous results as well with previous studies regarding endostatin’s effect 
(Dhanabal et al. 1999A, Dixelius et al. 2000). 
 
4.6 Endostatin, restin and heparin mutant endostatin influences endothelial 
morphology 
 
Concerning endothelium and vessel morphology we observed under influence of endostatin, 
restin and heparin mutant endostatin a contraction and retraction of endothelium and 
endothelial tubes using vital microscopic observation of in vitro differentiated embryonic stem 
cells and of new build vessels in wounded areas by ultra structural electron microscopy. 
During these observations only endothelial tubes and vessels of a defined differentiation 
degree were concerned. This finding was confirmed recently by a group of researchers who 
analyse vessel development in the eye of collagen XVIII knockout mice. It was noticed that 
collagen XVIII/endostatin is critical for normal blood vessel formation in the eye for a defined 
age or differentiation degree. Collagen XVIII/endostatin was not critical before birth but at 
postnatal day 4-8 (Fukai et al 2002).  
Under influence of endostatin, restin and the heparin mutant form of endostatin was observed 
a modulation of vascular morphology during wound healing as well as during vital 
microscopy of embryonic stem cell derived endothelial tubes in form of a contraction and 
vessel retraction. Morphological changes in form of a contraction were also observed by Read 
et al. 2001 after treatment with endostatin. They noticed that the contraction was not as an 
active process as we did by vital microscopy but in form of a reduces vessel diameter of 
tumour vessels. Also Bloch et al. 2000 observed narrowed and closed vessels on 
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ultrastructural level during wound healing after treatment with endostatin. Morphological 
changes under influence of endostatin could be explained by its above mentioned binding to 
tropomyosin (MacDonald et al. 2001). Tropomyosin, an endostatin binding protein plays an 
important role in contraction and morphogenesis of cells by influence on the regulation of the 
actin cytoskeleton (MacDonald et al. 2001). Additionally Mundhenke et al. 2001 detected 
changes of vessel morphology during wound healing after treatment with endostatin. But till 
now morphological changes in form of a dynamic process, the contraction of endothelial cells 
as well as the retraction of endothelial tubes has not been demonstrated. Also morphological 
changes under influence of restin and the heparin-binding mutant of endostatin were not 
described in the past. Because of the fact that inhibition of VEGF signaltransduction 
influences endothelial morphology and because of the down-regulation of the activated ERK-
1/2-kinase by the MAP-kinase inhibitor PD98059 lead to a comparable modulation of 
endothelial morphology, we concluded that endostatin-mediated effects on signaltransduction 
cause the observed retraction of endothelial cells and tubes.  
The effect of endostatin on vessel morphology could be a consequence of modulating 
signaltransduction and more precisely by influencing the VEGF signaltransduction. VEGF 
plays an important role regarding the morphogenesis of vasculo- and angiogenesis in the EB-
model (Kazemi et al. 2002) and in the embryo (Poole et al. 2001). Recently it was 
demonstrated that endostatin influences the VEGF signaling pathway by inhibition of the 
KDR/Flk-1 phoshorylation (Kim et al. 2002) and the phosphorylation of endothelial nitric 
oxide (Urbich et al. 2002).  
By vital microscopic analysis it was possible to observe that cGMP additionally was also able 
to inhibit the endostatin-mediated retraction of endothelial tubes. 
 
4.7 Signaltransduction under influence of endostatin, restin and heparin mutant 
endostatin 
 
It has been described for endostatin an effect on several signaling molecules is. Endostatin 
influences c-myc, c-fos, MAPK1 and 2 (Shichiri and Hirata 2001), activates PKA and 
increases intracellular cAMP (Shichire and Hirata 2001), increases Shb tyrosine 
phosphorylation (Dixelius et al. 2000) and increases Ca2+ influx (Jiang et al. 2001). Urbich et 
al. described an endostatin-mediated influence on eNOS-activity by modulation of the 
phosphorylation site at Ser1177 (Urbich et al. 2002). Shichiri and Hirata observed an 
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endostatin-mediated influence on MAPK 1 and 2 expression level (Shichiri and Hirata 2001) 
whereas we observed an endostatin-mediated influence on the activity of ERK1/2-kinase in 
form of a dephosphorylation of ERK1/2-kinase in endothelial cells and vessels during wound 
healing as well as for in vitro differentiated embryonic stem cells after treatment with 
endostatin. The down-regulation of sGC was demonstrated for the first time. The same effect 
could also be demonstrated for restin and the heparin mutant form of endostatin. Because of 
its influence on ERK1/2-kinase and sGC combined with the fact that vascular morphology is 
affected, which VEGF could be the responsible for, we concluded that this three proteins 
influence the VEGF/Flk-1/eNOS/sGC/cGMP/ERK pathway, which was described by Parenti 
et al. Also the fact that we were able to block endostatin-mediated influence of the ERK1/2-
kinase with additional cGMP and to block endostatin-mediated ERK1/2-kinase 
dephosphorylation with additional NO confirms these findings. The supposition that 
endostatin influences the VEGF signaling pathway described by Parenti is also confirmed by 
considering that cGMP plays an important role by the relaxation of vessels (Fullerton et al. 
1995, Brunner et al. 1996, Sheridan et al. 1997) whereas contraction of vessels under 
influence of endostatin was observed. The fact that inhibition of PP2A was able to block 
endostatin-mediated effects shows that these effects are induced by PP2A. To answer the 
question if the PP2A-induced dephosphorylation of ERK1/2-kinase is directly mediated by 
cGMP-reduction, we analysed if inhibition by ODQ is also able to dephosphorylate ERK1/2-
kinase. This was not the case. But we conclude that endostatin-mediated reduction of cGMP 
by deactivation of eNOS via PP2A only open up the possibility for PP2A to dephosphorylate 
ERK1/2-kinase. The fact that additional cGMP was able to block dephosphorylation of the 
activated ERK1/2-kinase but not the down-regulation of sGC and that inhibition of PP2A was 
able to block both endostatin-mediated effects we concluded that further pathways and 
mechanisms of regulation are involved in this complex regulation. 
Here we report about an endostatin-mediated dephosphorylation of ERK1/2-kinase and not 
about the absence of phosphorylation, which is related to our results concerning distribution 
of common ERK1/2-kinase and activated/phosporylated ERK1/2-kinase. Common ERK1/2-
kinase was not reduced after treatment with endostatin whereas the activated form was. This 
makes clear that the endostatin-mediated effect concerning ERK1/2-kinase is a 
dephosphorylation. Concerning sGC we observed a down-regulation within 6 hours after 
treatment with endostatin. This period of time was also observed for sGC down-regulation 
under influence of 17ß-estradiol (E2) in rat uterus (Krumenacker et al. 2001). Krumenacker et 
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al. concluded from this period of time that decrease in sGC protein level occurs as a result of 
the reduction of mRNA level. Therefore we analysed by using RT in situ PCR if the mRNA 
level of sGCalpha1 and sGCbeta1 was changed after treatment with endostatin, what was not 
the case. Therefore the down-regulation of sGC under influence of endostatin could 
presumably be a consequence of a modification on protein level.  
The angiogenesis inhibitor thrombospondin also influence signaling molecules and lead to 
phosphorylation of ERK1/2-kinase (Orr et al. 2002), whereas angiostatin described as anti-
angiogenic and tumour inhibitory diminishes ERK1/2-phosphorylation (Redlitz et al. 1999) 
 
5. Conclusion  
 
The proteolytic fragments of collagen XVIII and XV, endostatin and restin, play an important 
role for embryonic vasculo- and angiogenesis as well as during regenerativ neovascularisation 
of physiological wound healing. It could be shown that it influences ES-cell derived 
endothelial cells and neovasculatur of wounded tissue in a pro- as well as anti-angiogenic 
fashion, suggesting an angio-modulatory role. Endostatin increases proliferation, the amount 
of vessels and migration but also apoptosis, contraction and morphological changes.  
By inhibiting VEGF signaltransduction and especially by dephosphorylate ERK1/2-kinase via 
PP2A, endostatin presumably influences endothelial morphology. Summarising our 
observations, we conclude that the endostatin-mediated down-regulation of cGMP by 
reduction of eNOS activity via PP2A can only open up the possibility for the PP2A effect of 
ERK1/2-kinase dephosphorylation. The PP2A-mediated dephosphorylation of ERK1/2 in 
endothelial cells presumably is cGMP-dependent, but not directly cGMP-mediated. 
The present study exemplifies that endostatin, restin and other endothelium influencing 
factors must be examined taking into account differentiation stage, signaltransduction and the 
origin of cells. These various factors may strongly determine the biological outcome. 
An important fact regarding tumour therapies is that different tumours do not express binding 
sites in an amount, which is sufficient to address this kind of tumours by a treatment with 
endostatin and restin. From that we can learn, that a tumour therapy with such substances 
cannot be a uniform treatment, it must be individually adjusted to the type of tumour and the 
origin of tumour. 
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6. Outlook 
 
An unclear but important question rises during this work: “Is the down-regulation of sGC 
under influence of endostatin a consequence of a modification on protein level?“ Answering 
this question was planed, but unfortunately till now not practicable. From personal comments 
(NO-Forum, 2002, in Frankfurt, abstract) it was known, that HSP90 stabilizes sGC protein in 
endothelial cells. Therefore we are interested to see if inhibition of HSP90 using 
geldanamycin also leads to a down-regulation of sGC in a comparable time course, which 
would imply prevention or disturbing of HSP90. Another important point is the role of protein 
modification by proteasoma. In order to examine this problem we are interested if the 
proteasoma inhibitor MG132, which reduces the degradation of ubiquitin-conjugated proteins, 
is able to block the endostatin-mediated down-regulation of sGC. This would show us that the 
endostatin-mediated down-regulation is a consequence of modification on protein level. 
Raf-1 is influenced by endostatin by binding to alpha5beta1 integrin (Sudhaker et al. 2003). 
PP2A is a positive regulator of Raf-1 activation (Abraham et al. 2000). It would be interesting 
to analyse if there are connections or overlaps between these regulatory ways. 
Another interesting point would be to examine the role for the protein phosphatase Shp-1 on 
endostatin-mediated effects. Shp-1 is also influenced by endostatin and is standing in 
connection with both, sGC and the activated ERK1/2-kinase. Information’s about this 
regulation could help us to verify if the described signaling pathway is the only involved, or if 
other pathways are implicated. 
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